

ALLNAMES:(Astute Medical, Inc.)

655 results Offices all Languages en Stemming true Single Family Member false Include NPL false

Sort: Relevance

Per page: 200

View: All

1 / 4

Machine translation

1. [20200071416](#) ASSAYS FOR TIMP2 HAVING IMPROVED PERFORMANCE IN BIOLOGICAL SAMPLES US - 05.03.2020Int.Class [C07K 16/30](#) Appl.No 16603071 Applicant ASTUTE MEDICAL, INC. Inventor RAVI A. VIJAYENDRAN

The present invention relates to antibodies or antigen binding fragments thereof that binds to human "TIMP2. Further provided are methods for treating subjects, including human subjects, in need of treatment with the isolated TIMP2 antibodies or antigen-binding fragments thereof disclosed herein. Further provided are pharmaceutical or sterile compositions of anti-TIMP2 antibodies and antigen-binding fragments of the invention, the antibody or antigen-binding fragment thereof is admixed with a pharmaceutically acceptable carrier or excipient. Further provided are kits comprising one or more components that include an anti-TIMP2 antibody or antigen-binding fragment thereof of the invention or a pharmaceutical composition thereof.

2. [3606554](#) ASSAYS FOR TIMP2 HAVING IMPROVED PERFORMANCE IN BIOLOGICAL SAMPLES EP - 12.02.2020Int.Class [C07K 16/30](#) Appl.No 18781904 Applicant ASTUTE MEDICAL INC Inventor VIJAYENDRAN RAVI A

The present invention relates to antibodies or antigen binding fragments thereof that binds to human "TIMP2. Further provided are methods for treating subjects, including human subjects, in need of treatment with the isolated TIMP2 antibodies or antigen-binding fragments thereof disclosed herein. Further provided are pharmaceutical or sterile compositions of anti-TIMP2 antibodies and antigen-binding fragments of the invention, the antibody or antigen-binding fragment thereof is admixed with a pharmaceutically acceptable carrier or excipient. Further provided are kits comprising one or more components that include an anti-TIMP2 antibody or antigen-binding fragment thereof of the invention or a pharmaceutical composition thereof.

3. [201937041368](#) ASSAYS FOR TIMP2 HAVING IMPROVED PERFORMANCE IN BIOLOGICAL SAMPLES IN - 06.12.2019Int.Class [A61K 39/395](#) Appl.No 201937041368 Applicant ASTUTE MEDICAL, INC. Inventor VIJAYENDRAN, Ravi A.

The present invention relates to antibodies or antigen binding fragments thereof that binds to human "TIMP2. Further provided are methods for treating subjects including human subjects in need of treatment with the isolated TIMP2 antibodies or antigen-binding fragments thereof disclosed herein. Further provided are pharmaceutical or sterile compositions of anti-TIMP2 antibodies and antigen-binding fragments of the invention the antibody or antigen-binding fragment thereof is admixed with a pharmaceutically acceptable carrier or excipient. Further provided are kits comprising one or more components that include an anti-TIMP2 antibody or antigen-binding fragment thereof of the invention or a pharmaceutical composition thereof.

4. [WO/2016/176483](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE WO - 03.11.2016Int.Class [G01N 33/48](#) Appl.No PCT/US2016/029839 Applicant ASTUTE MEDICAL, INC. Inventor ANDERBERG, Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more of Dickkopf-related protein 1, Nidogen-1, and CD97 as diagnostic and prognostic biomarker assays in renal injuries.

5. [WO/2018/187453](#) ASSAYS FOR TIMP2 HAVING IMPROVED PERFORMANCE IN BIOLOGICAL SAMPLES WO - 11.10.2018Int.Class [A61K 39/395](#) Appl.No PCT/US2018/026058 Applicant ASTUTE MEDICAL, INC. Inventor VIJAYENDRAN, Ravi A.

The present invention relates to antibodies or antigen binding fragments thereof that binds to human "TIMP2. Further provided are methods for treating subjects, including human subjects, in need of treatment with the isolated TIMP2 antibodies or antigen-binding fragments thereof disclosed herein. Further provided are pharmaceutical or sterile compositions of anti-TIMP2 antibodies and antigen-binding fragments of the invention, the antibody or antigen-binding fragment thereof is admixed with a pharmaceutically acceptable carrier or excipient. Further provided are kits comprising one or more components that include an anti-TIMP2 antibody or antigen-binding fragment thereof of the invention or a pharmaceutical composition thereof.

6. [255/MUMNP/2012](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE IN - 24.08.2012Int.Class [G01N 33/50](#) Appl.No 255/MUMNP/2012 Applicant ASTUTE MEDICAL INC. Inventor ANDERBERG Joseph

The present invention relates to methods and compositions for monitoring diagnosis prognosis and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular the invention relates to using assays that detect Beta-2-glycoprotein 1 as a diagnostic and prognostic biomarker in renal injuries.

7. [625771](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE NZ - 12.06.2014Int.Class [G01N 33/50](#) Appl.No 625771 Applicant Astute Medical, Inc. Inventor ANDERBERG, Joseph

8. [2770393](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE CA - 10.02.2011

Int.Class [G01N 33/48](#) Appl.No 2770393 Applicant ASTUTE MEDICAL, INC. Inventor ANDERBERG, JOSEPH

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect Beta-2-glycoprotein 1 as a diagnostic and prognostic biomarker in renal injuries.

9. [2462440](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE EP - 13.06.2012

Int.Class [G01N 33/68](#) Appl.No 10807254 Applicant ASTUTE MEDICAL INC Inventor ANDERBERG JOSEPH

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect Beta-2-glycoprotein 1 as a diagnostic and prognostic biomarker in renal injuries.

10. [598034](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE NZ - 27.06.2014

Int.Class [G01N 33/50](#) Appl.No 598034 Applicant Astute Medical, Inc. Inventor ANDERBERG, Joseph

Disclosed is an ex vivo method for evaluating renal status in a subject, comprising: performing an assay method configured to detect Beta-2-glycoprotein 1, the assay comprising contacting a body fluid sample obtained previously from a subject with an antibody or fragment thereof capable of binding a kidney injury marker consisting of Beta-2-glycoprotein-1 under conditions sufficient for the antibody or fragment thereof to bind selectively to the kidney injury marker; determining an assay result that is a measured concentration of the Beta-2-glycoprotein-1 in the body fluid sample, said assay result being determined from an amount of the antibody or fragment bound to the kidney injury marker; correlating the assay result to the renal status of the subject by comparing the measured concentration of Beta-2-glycoprotein-1 in said assay result to a threshold concentration of Beta-2-glycoprotein-1; and: [i] assigning an increased likelihood of an event occurring or having occurred when the measured concentration is above the threshold, wherein the event is associated with reduced renal function; and/or [ii] assigning a decreased likelihood of an event occurring or having occurred when the measured concentration is below the threshold, wherein the event is associated with reduced renal function; and/or [iii] assigning an increased likelihood of an event occurring or having occurred when the measured concentration is below the threshold, wherein the event is associated with an improvement in renal function; and/or [iv] assigning a decreased likelihood of an event occurring or having occurred when the measured concentration is above the threshold, wherein the event is associated with an improvement in renal function.

11. [20150044706](#) METHODS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE US - 12.02.2015

Int.Class [G01N 33/68](#) Appl.No 14524031 Applicant ASTUTE MEDICAL, INC. Inventor Joseph Anderberg

The present invention relates to methods and compositions for monitoring subjects suffering from a renal injury. In particular, the invention relates to using assays that detect Beta-2-glycoprotein 1 as a prognostic biomarker in renal injuries.

12. [336280](#) METODOS Y COMPOSICIONES PARA DIAGNOSTICOS Y PRONOSTICOS DE LESION RENAL Y FALLA RENAL. MX - 13.01.2016

Int.Class [C12Q 1/37](#) Appl.No 2012001559 Applicant ASTUTE MEDICAL, INC. Inventor ANDERBERG, Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect Beta-2-glycoprotein 1 as a diagnostic and prognostic biomarker in renal injuries.

13. [102576011](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE CN - 11.07.2012

Int.Class [G01N 33/50](#) Appl.No 201080037448.0 Applicant Astute Medical Inc. Inventor Anderberg Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect Beta-2-glycoprotein 1 as a diagnostic and prognostic biomarker in renal injuries.

14. [2010279249](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE AU - 01.03.2012

Int.Class [G01N 33/50](#) Appl.No 2010279249 Applicant Astute Medical, Inc. Inventor Anderberg, Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect Beta-2-glycoprotein 1 as a diagnostic and prognostic biomarker in renal injuries.

15. [112012002711](#) METODO PARA AVALIAR O ESTADO RENAL EM UM INDIVIDUO, E, MEDICAO DE PROTEINA BR - 01.11.2016

Int.Class [G01N 33](#) Appl.No 112012002711 Applicant Astute Medical, Inc Inventor Jeff Gray

abstract not available

16. [20150293131](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF SEPSIS US - 15.10.2015

Int.Class [G01N 33/92](#) Appl.No 14390338 Applicant ASTUTE MEDICAL, INC. Inventor Joseph Anderberg

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in sepsis patients and in patients at risk for sepsis. In particular, the invention relates to using assays that detect one or more biomarkers as diagnostic and prognostic biomarker assays in such patients.



17. [20180095093](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE US - 05.04.2018

Int.Class [G01N 33/68](#) Appl.No 15573441 Applicant ASTUTE MEDICAL, INC. Inventor Joseph Anderberg

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more of Insulin-like growth factor-binding protein 2, Insulin-like growth factor-binding protein 3, Insulinlike growth factor-binding protein 4, and Insulin like growth factor-binding protein 6 as diagnostic and prognostic biomarker assays in renal injuries.

18. [2015210483](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE AU - 27.08.2015

Int.Class [G01N 33/53](#) Appl.No 2015210483 Applicant Astute Medical, Inc. Inventor Anderberg, Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a plurality of assays configured to detect a kidney injury marker as diagnostic and prognostic biomarkers in renal injuries.

19. [2015203382](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE AU - 09.07.2015

Int.Class [G01N 33/48](#) Appl.No 2015203382 Applicant Astute Medical, Inc. Inventor Anderberg, Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Tumor necrosis factor receptor superfamily member 8, Alpha-Fetoprotein, Thyroxine-binding globulin, Prostate-specific antigen (free form), Apolipoprotein A, Apolipoprotein E, Thyrotropin subunit beta, Platelet-derived growth factor B/B dimer, C-C motif chemokine 7, C-C motif chemokine 26, Complement C4-B, Corticotropin, Interferon alpha-2, Interleukin-4 receptor alpha chain, Insulin-like growth factor binding protein 4, Insulin-like growth factor-binding protein 5, Interleukin 21, Interleukin 23 alpha subunit, Interleukin-28A, Interleukin-33, Lutropin subunit beta, Matrix Metalloproteinase- 1, Neural cell adhesion molecule 1, Pigment epithelium derived factor, Vascular endothelial growth factor receptor 2, Vascular endothelial growth factor receptor 3, and IgG4 as diagnostic and prognostic biomarkers in renal injuries.

20. [3070474](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE EP - 21.09.2016

Int.Class [G01N 33/68](#) Appl.No 15190063 Applicant ASTUTE MEDICAL INC Inventor ANDERBERG JOSEPH

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using one or more assay configured to detect a kidney injury marker as diagnostic and prognostic biomarker in renal injuries.

21. [20160018412](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE US - 21.01.2016

Int.Class [G01N 33/68](#) Appl.No 14708225 Applicant ASTUTE MEDICAL, INC. Inventor Joseph Anderberg

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a plurality of assays configured to detect a kidney injury marker as diagnostic and prognostic biomarkers in renal injuries.

22. [720355](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE NZ - 08.12.2017

Int.Class [G01N 33/53](#) Appl.No 720355 Applicant Astute Medical, Inc. Inventor ANDERBERG, Joseph

23. [602056](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE NZ - 28.11.2014

Int.Class [G01N 33/53](#) Appl.No 602056 Applicant Astute Medical, Inc. Inventor ANDERBERG, Joseph

Disclosed is an ex vivo method for evaluating renal status in a subject, said method comprising detecting Antileukoproteinase [SLPI] and Thrombomodulin [CD41] in a sample, determining the concentration of Thrombomodulin and Antileukoproteinase and determining the renal status according to the specific methods as described herein. Further disclosed is the combined use of antibodies or antibody fragments in a method performed ex vivo on one or more body fluid samples obtained previously from a subject in determining a present or future reduced renal function in the subject, wherein the antibodies or antibody fragments bind independently to: (i) Thrombomodulin or an epitope thereof; and (ii) Antileukoproteinase or an epitope thereof.

24. [701807](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE NZ - 29.05.2015

Int.Class [G01N 33/53](#) Appl.No 701807 Applicant Astute Medical, Inc. Inventor ANDERBERG, Joseph

Disclosed is a method for evaluating renal status in a subject ex vivo, comprising: performing one or more assays configured to detect one or more kidney injury markers in a body fluid sample obtained previously from the subject, wherein at least one of said kidney injury markers is WAP four-disulfide core domain protein 2; determining on the body fluid sample one or more assay results(s); and correlating the assay results to the renal status of the subject, said correlating comprising comparing a measured concentration of WAP four-disulfide core domain protein 2 to a threshold concentration of WAP four-disulfide core domain protein 2 and assigning a likelihood of an event occurring or assigning a likelihood of an event not occurring when the measured concentration varies from the threshold.

25. [705411](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE NZ - 24.06.2016



Int.Class [G01N 33/53](#) Appl.No 705411 Applicant Astute Medical, Inc. Inventor ANDERBERG, Joseph

Disclosed is a method for evaluating renal status in a subject ex vivo, comprising: performing one or more assays configured to detect the kidney injury markers Metalloproteinase inhibitor 2 (TIMP2) and Thrombospondin 1 (THBS1) in a body fluid sample obtained previously from the subject; determining on the body fluid sample one or more assay result(s); and correlating the assay result(s) to the renal status of the subject, said correlating comprising comparing a measured concentration of Metalloproteinase inhibitor 2 to a threshold concentration of Metalloproteinase inhibitor 2, comparing a measured concentration of Thrombospondin 1 to a threshold concentration of Thrombospondin 1 and assigning a likelihood of an event occurring or assigning a likelihood of an event not occurring when the measured concentration varies from the threshold.

26. [2015203814](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE AU - 23.07.2015

Int.Class [G01N 33/53](#) Appl.No 2015203814 Applicant Astute Medical, Inc. Inventor Anderberg, Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more biomarkers selected from the group consisting of Beta-nerve growth factor, Interleukin-17A, Follitropin subunit beta, Collagenase 3, Follistatin, Vitamin D Binding Protein, Islet amyloid polypeptide, Insulin C-peptide, Complement Factor H, Gastric inhibitory polypeptide, Glucagon-like peptide 1, Glucagon, Involucrin, Type II cytoskeletal Keratin-1/Keratin-10, Type II cytoskeletal Keratin-6A/6B/6C, Osteocalcin, Lipopolysaccharide, Pancreatic prohormone, Peptide YY, Agouti-related protein, Ciliary neurotrophic factor, Appetite-regulating hormone, Transthyretin, Insulin receptor substrate 1, and NF-kappa-B inhibitor alpha as diagnostic and prognostic biomarker assays in renal injuries.

27. [2015204291](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE AU - 30.07.2015

Int.Class [G01N 33/48](#) Appl.No 2015204291 Applicant Astute Medical, Inc. Inventor Anderberg, Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Cancer antigen CA 15-3, C-C Motif chemokine 18, C-C Motif chemokine 24, Cathepsin D, C-X-C Motif chemokine 13, C-C motif chemokine 8, Interleukin-2 receptor alpha chain, Insulin-like growth factor-binding protein 3, Interleukin-11, Matrix Metalloproteinase-8, Transforming growth factor alpha, IgG1, and IgG2 as diagnostic and prognostic biomarkers in renal injuries.

28. [2011220413](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE AU - 20.09.2012

Int.Class [G01N 33/53](#) Appl.No 2011220413 Applicant Astute Medical, Inc. Inventor Anderberg, Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a plurality of assays configured to detect a kidney injury marker as diagnostic and prognostic biomarkers in renal injuries.

29. [20150177260](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF SEPSIS US - 25.06.2015

Int.Class [G01N 33/68](#) Appl.No 14416988 Applicant ASTUTE MEDICAL, INC. Inventor Joseph Anderberg

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in sepsis patients and in patients at risk for sepsis. In particular, the invention relates to using assays that detect one or more of WAP four-disulfide core domain protein 2, Hepatitis A virus cellular receptor 1, Interleukin-1 receptor-like 1, and Proprotein convertase subtilisin/kexin type 9 as diagnostic and prognostic in such patients.

30. [2539712](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE EP - 02.01.2013

Int.Class [G01N 33/68](#) Appl.No 11748210 Applicant ASTUTE MEDICAL INC Inventor ANDERBERG JOSEPH

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a plurality of assays configured to detect a kidney injury marker as diagnostic and prognostic biomarkers in renal injuries.

31. [2790785](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE CA - 01.09.2011

Int.Class [G01N 33/48](#) Appl.No 2790785 Applicant ASTUTE MEDICAL, INC. Inventor ANDERBERG, JOSEPH

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a plurality of assays configured to detect a kidney injury marker as diagnostic and prognostic biomarkers in renal injuries.

32. [107735147](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE CN - 23.02.2018

Int.Class [A61P 13/12](#) Appl.No 201680038773.6 Applicant ASTUTE MEDICAL INC. Inventor ANDERBERG JOSEPH

The invention relates to methods and compositions for diagnosis and prognosis of renal injury and renal failure. The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more of Insulin-like growth factor-binding protein 2, Insulin-like growth factor-binding protein 3, Insulin-like growth factor-binding protein 4, and Insulin like growth factor-binding protein 6 as diagnostic and prognostic biomarker assays in renal injuries.

33. [WO/2016/183377](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND WO - 17.11.2016



## RENAL FAILURE

Int.Class [A61P 13/12](#) Appl.No PCT/US2016/032209 Applicant ASTUTE MEDICAL, INC. Inventor ANDERBERG, Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more of Insulin-like growth factor-binding protein 2, Insulin-like growth factor-binding protein 3, Insulin-like growth factor-binding protein 4, and Insulin like growth factor-binding protein 6 as diagnostic and prognostic biomarker assays in renal injuries.

34. [WO/2016/130802](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE WO - 18.08.2016

Int.Class [G01N 33/53](#) Appl.No PCT/US2016/017546 Applicant ASTUTE MEDICAL, INC. Inventor ANDERBERG, Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more of WAP four-disulfide core domain protein 2, Annexin A2, and Syndecan-1 as diagnostic and prognostic biomarker assays in renal injuries.

35. [20220155324](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE US - 19.05.2022

Int.Class [G01N 33/68](#) Appl.No 17494773 Applicant ASTUTE MEDICAL, INC. Inventor JOSEPH ANDERBERG

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more of Insulin-like growth factor-binding protein 2, Insulin-like growth factor-binding protein 3, Insulin-like growth factor-binding protein 4, and Insulin like growth factor-binding protein 6 as diagnostic and prognostic biomarker assays in renal injuries.

36. [WO/2014/018464](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF SEPSIS WO - 30.01.2014

Int.Class [G01N 33/00](#) Appl.No PCT/US2013/051546 Applicant ASTUTE MEDICAL, INC. Inventor ANDERBERG, Joseph

The present disclosure relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in sepsis patients and in patients at risk for sepsis. In particular, the method relates to using assays that detect one or more of WAP four-disulfide core domain protein 2, Hepatitis A virus cellular receptor 1, Interleukin-1 receptor-like 1, and Proprotein convertase subtilisin/kexin type 9 as diagnostic and prognostic in such patients.

37. [3572809](#) METHODS FOR DIAGNOSIS OF SEPSIS EP - 27.11.2019

Int.Class [G01N 33/00](#) Appl.No 19158543 Applicant ASTUTE MEDICAL INC Inventor ANDERBERG JOSEPH

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in sepsis patients and in patients at risk for sepsis. In particular, the invention relates to using assays that detect one or more of WAP four-disulfide core domain protein 2, Hepatitis A virus cellular receptor 1, Interleukin-1 receptor-like 1, and Proprotein convertase subtilisin/kexin type 9 as diagnostic and prognostic in such patients.

38. [2875347](#) METHODS FOR DIAGNOSIS OF SEPSIS EP - 27.05.2015

Int.Class [G01N 33/00](#) Appl.No 13823735 Applicant ASTUTE MEDICAL INC Inventor ANDERBERG JOSEPH

The present disclosure relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in sepsis patients and in patients at risk for sepsis. In particular, the method relates to using assays that detect one or more of WAP four-disulfide core domain protein 2, Hepatitis A virus cellular receptor 1, Interleukin-1 receptor-like 1, and Proprotein convertase subtilisin/kexin type 9 as diagnostic and prognostic in such patients.

39. [3294416](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE EP - 21.03.2018

Int.Class [A61P 13/12](#) Appl.No 16793563 Applicant ASTUTE MEDICAL INC Inventor ANDERBERG JOSEPH

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more of Insulin-like growth factor-binding protein 2, Insulin-like growth factor-binding protein 3, Insulin-like growth factor-binding protein 4, and Insulin like growth factor-binding protein 6 as diagnostic and prognostic biomarker assays in renal injuries.

40. [2542697](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE IN A NON-SURGICAL ICU POPULATION EP - 09.01.2013

Int.Class [C12Q 1/68](#) Appl.No 11751238 Applicant ASTUTE MEDICAL INC Inventor ANDERBERG JOSEPH

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects admitted to a hospital critical care setting for other than a post-surgical or trauma indication. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Insulin-like growth factor IA, soluble Epidermal growth factor receptor, and Leukocyte elastase as diagnostic and prognostic biomarkers in renal injuries.

41. [2013202655](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE AU - 18.04.2013

Int.Class [G01N 33/48](#) Appl.No 2013202655 Applicant Astute Medical, Inc. Inventor



[00150] The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Cytoplasmic aspartate aminotransferase, soluble Tumor necrosis factor receptor superfamily member 5, soluble CD40 Ligand, soluble C-X-C Motif chemokine 16, S100-A12, Eotaxin, soluble E-selectin, Fibronectin, Granulocyte colony-stimulating factor, Granulocyte-macrophage colony-stimulating factor, Heparin-binding growth factor 2, soluble Hepatocyte growth factor receptor, Interleukin-1 receptor antagonist, Interleukin-1 beta, Interleukin 10, Interleukin-15, Interleukin-3, Myeloperoxidase, Nidogen-1, soluble Oxidized low-density lipoprotein receptor 1, Pappalysin-1, soluble P-selectin glycoprotein ligand 1, Antileukoproteinase, soluble Kit ligand, Tissue inhibitor of metalloproteinase 1, Tissue inhibitor of metalloproteinase 2, soluble Tumor necrosis factor, soluble Vascular cell adhesion molecule 1, and Vascular endothelial growth factor A as diagnostic and prognostic biomarkers in renal injuries.

42. [2009316387](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE AU - 26.05.2011

Int.Class [C12Q 1/68](#) Appl.No 2009316387 Applicant Astute Medical, Inc. Inventor Anderberg, Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Epidermal growth factor, Complement C3, Interleukin-4, Interleukin- 1 alpha, Tubulointerstitial nephritis antigen, Transforming growth factor beta-1, Bone morphogenetic protein 7, Osteopontin, Netrin-1, and Growth-regulated alpha protein as diagnostic and prognostic biomarkers in renal injuries.

43. [1262/MUMNP/2011](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE IN - 17.08.2012

Int.Class [C12Q 1/68](#) Appl.No 1262/MUMNP/2011 Applicant ASTUTE MEDICAL INC. Inventor ANDERBERG Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Epidermal growth factor, Complement C3, Interleukin-4, Interleukin- 1 alpha, Tubulointerstitial nephritis antigen, Transforming growth factor beta-1, Bone morphogenetic protein 7, Osteopontin, Netrin-1, and Growth-regulated alpha protein as diagnostic and prognostic biomarkers in renal injuries.

44. [PI0921921](#) MÉTODO PARA AVALIAR A CONDIÇÃO RENAL EM UM INDIVÍDUO, E, USO DE UM OU MAIS MARCADORES DE LESÃO RENAL. BR - 24.09.2019

Int.Class [C12Q 1](#) Appl.No PI0921921 Applicant Astute Medical, INC. Inventor Jeff Gray

abstract not available

45. [2324354](#) METHODS FOR PROGNOSIS OF ACUTE RENAL FAILURE EP - 25.05.2011

Int.Class [G01N 33/53](#) Appl.No 09810705 Applicant ASTUTE MEDICAL INC Inventor ANDERBERG JOSEPH

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of cytochrome c and insulin-like growth factor IA as diagnostic and prognostic biomarkers in renal injuries.

46. [2813848](#) METHODS FOR PROGNOSIS OF RENAL FAILURE EP - 17.12.2014

Int.Class [G01N 33/53](#) Appl.No 14176863 Applicant ASTUTE MEDICAL INC Inventor ANDERBERG JOSEPH

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of cytochrome c and insulin-like growth factor IA as diagnostic and prognostic biomarkers in renal injuries.

47. [20150285824](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE US - 08.10.2015

Int.Class [G01N 33/53](#) Appl.No 14738904 Applicant ASTUTE MEDICAL, INC. Inventor Joseph Anderberg

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of cytochrome c and insulin-like growth factor IA as diagnostic and prognostic biomarkers in renal injuries.

48. [2735590](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE CA - 04.03.2010

Int.Class [G01N 33/48](#) Appl.No 2735590 Applicant ASTUTE MEDICAL, INC. Inventor ANDERBERG, JOSEPH

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of cytochrome c and insulin-like growth factor IA as diagnostic and prognostic biomarkers in renal injuries.

49. [1672/CHENP/2011](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE IN - 02.12.2011

Int.Class [G01N 33/53](#) Appl.No 1672/CHENP/2011 Applicant ASTUTE MEDICAL INC Inventor ANDERBERG, JOSEPH



50. [2011005379](#) METODOS Y COMPOSICIONES PARA DIAGNOSIS Y PROGNOSIS DE LESION RENAL Y FALLA RENAL. MX - 09.06.2011

Int.Class [C12Q 1/68](#) Appl.No 2011005379 Applicant ASTUTE MEDICAL, INC.\* Inventor ANDERBERG, Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Epidermal growth factor, Complement C3, Interleukin-4, Interleukin- 1 alpha, Tubulointerstitial nephritis antigen, Transforming growth factor beta-1, Bone morphogenetic protein 7, Osteopontin, Netrin-1, and Growth-regulated alpha protein as diagnostic and prognostic biomarkers in renal injuries.

51. [592552](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE NZ - 20.12.2013

Int.Class [C12Q 1/68](#) Appl.No 592552 Applicant Astute Medical, Inc. Inventor ANDERBERG, Joseph

NZ 592552 Disclosed is a method for determining a likelihood of a future acute change in renal function in a subject, said method comprising: performing one or more assays configured to detect a growth-regulated alpha protein, each assay comprising contacting ex vivo a body fluid sample comprising urine or plasma obtained previously from a subject with an antibody or fragment thereof capable of binding to growth-regulated alpha protein under conditions sufficient for the antibody or fragment thereof to bind selectively to the kidney injury marker; determining results of the one or more assays, each assay result comprising a measured amount of the antibody or fragment thereof bound to a growth-regulated alpha protein; correlating the assay results to a measured concentration of a growth-regulated alpha protein in the body fluid sample; and assigning an increased likelihood of a future acute change in renal function in the subject when the measured concentration in the sample is above the threshold relative to a likelihood thereof when the measured concentration is below the threshold; or assigning a decreased likelihood of a future acute change in renal function in the subject when the measured concentration in the sample is below the threshold, relative to a likelihood thereof when the measured concentration is above the threshold. The disclosed method is subject to the proviso that the subject is not a renal transplant recipient and subject to the proviso that the subject does not have a pre-diagnosed acute kidney injury (AKI) or pre-diagnosed acute renal failure (ARF) when the body fluid sample is taken.

52. [104034901](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE CN - 10.09.2014

Int.Class [G01N 33/68](#) Appl.No 201410171137.3 Applicant ASTUTE MEDICAL, INC. Inventor ANDERBERG JOSEPH

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Epidermal growth factor, Complement C3, Interleukin-4, Interleukin-1 alpha, Tubulointerstitial nephritis antigen, Transforming growth factor beta-1, Bone morphogenetic protein 7, Osteopontin, Netrin-1, and Growth-regulated alpha protein as diagnostic and prognostic biomarkers in renal injuries.

53. [2528799](#) MÉTODOS PARA EL PRONÓSTICO DE INSUFICIENCIA RENAL AGUDA ES - 12.02.2015

Int.Class [C12Q 1/68](#) Appl.No 09828325 Applicant Astute Medical, Inc. Inventor ANDERBERG, Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Epidermal growth factor, Complement C3, Interleukin-4, Interleukin- 1 alpha, Tubulointerstitial nephritis antigen, Transforming growth factor beta-1, Bone morphogenetic protein 7, Osteopontin, Netrin-1, and Growth-regulated alpha protein as diagnostic and prognostic biomarkers in renal injuries.

54. [604873](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE NZ - 30.05.2014

Int.Class [C12Q 1/68](#) Appl.No 604873 Applicant Astute Medical, Inc. Inventor ANDERBERG, Joseph

Disclosed is a method for evaluating an acute change in renal function of a subject or a risk thereof, said method comprising: A. performing an assay comprising contacting a body fluid sample obtained previously from the subject with a species comprising an antibody or fragment thereof that binds to Complement C3 under conditions sufficient for the species to bind selectively to Complement C3 present in the body fluid sample thereby detecting the Complement C3; B. determining an amount of the species bound to the Complement C3; C. correlating the amount of the species bound to Complement C3 to a measured concentration of Complement C3 in the body fluid sample; and (i) assigning an increased likelihood of an acute reduction in renal function occurring in the subject when the measured concentration of Complement C3 in the sample is above a threshold concentration relative to a likelihood thereof when the measured concentration is below the threshold, or determining that an acute reduction in renal function has occurred in the subject when the measured concentration of Complement C3 in the sample is above a threshold concentration, to thereby evaluate an acute change in renal status of the subject; or (ii) assigning a decreased likelihood of an acute reduction in renal function of the subject when the measured concentration in the sample is below a threshold concentration relative to a likelihood thereof when the measured concentration is above the threshold, or determining that an acute reduction in renal function has not occurred in the subject when the measured concentration of Complement C3 in the sample is below a threshold concentration, to thereby evaluate an acute change in renal status of the subject.

55. [624159](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE NZ - 29.01.2016

Int.Class [C12Q 1/68](#) Appl.No 624159 Applicant Astute Medical, Inc. Inventor ANDERBERG, Joseph

A method for evaluating renal status in a subject ex vivo, comprises performing one or more assays configured to detect a kidney injury marker on a body fluid sample obtained previously from the subject to provide one or more assay results, the kidney injury marker being Epidermal growth factor; and correlating the assay result(s) to one or more of risk stratification, staging, prognosis, classifying and monitoring of the renal status of the subject. The correlating step comprises assigning a likelihood or risk of future acute renal failure (ARF) suffered by the subject.

56. [2811036](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE EP - 10.12.2014

Int.Class [C12Q 1/68](#) Appl.No 14181027 Applicant ASTUTE MEDICAL INC Inventor GRAY JEFF

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect Growth-regulated alpha protein as well as optionally one or more of Epidermal growth factor, Complement C3, Interleukin-4, Interleukin-1 alpha, Tubulointerstitial nephritis antigen, Transforming growth factor bet-1, Bone morphogenetic protein 7, Osteopontin, and Netrin-1, as diagnostic and prognostic biomarkers in renal injuries.



57. [2015202151](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE AU - 14.05.2015

Int.Class [C12Q 1/68](#) Appl.No 2015202151 Applicant Astute Medical, Inc. Inventor Anderberg, Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Epidermal growth factor, Complement C3, Interleukin-4, Interleukin- 1 alpha, Tubulointerstitial nephritis antigen, Transforming growth factor beta-1, Bone morphogenetic protein 7, Osteopontin, Netrin-1, and Growth-regulated alpha protein as diagnostic and prognostic biomarkers in renal injuries.

58. [2012340748](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE AU - 26.06.2014

Int.Class [G01N 33/53](#) Appl.No 2012340748 Applicant Astute Medical, Inc. Inventor Anderberg, Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Stanniocalcin- 1, Antithrombin-III, Toll-like receptor 2, Triiodothyronine [T3], Thyroxine [T4], Extracellular matrix protein 1, Coagulation factor XIII A chain, Coagulation factor XIII B chain, Interleukin-17F, Interleukin-22, Vitronectin, Progesterone, Estradiol, Growth/differentiation factor 15, and Proprotein convertase subtilisin/kexin type 9 as diagnostic and prognostic biomarkers in renal injuries.

59. [3282257](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE EP - 14.02.2018

Int.Class [G01N 33/68](#) Appl.No 17190074 Applicant ASTUTE MEDICAL INC Inventor ANDERBERG JOSEPH

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect Growth/differentiation factor 15, and optionally further a kidney injury marker of Stanniocalcin-1, Antithrombin-III, Toll-like receptor 2, Triiodothyronine [T3], Thyroxine [T4], Extracellular matrix protein 1, Coagulation factor XIII A chain, Coagulation factor XIII B chain, Interleukin-17F, Interleukin-22, Vitronectin, Progesterone, Estradiol, and Proprotein convertase subtilisin/kexin type 9 as diagnostic and prognostic biomarkers in renal injuries.

60. [949/MUMNP/2014](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE IN - 24.04.2015

Int.Class [G01N 33/53](#) Appl.No 949/MUMNP/2014 Applicant ASTUTE MEDICAL INC. Inventor ANDERBERG Joseph

The present invention relates to methods and compositions for monitoring diagnosis prognosis and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Stanniocalcin 1 Antithrombin III Toll like receptor 2 Triiodothyronine [T3] Thyroxine [T4] Extracellular matrix protein 1 Coagulation factor XIII A chain Coagulation factor XIII B chain Interleukin 17F Interleukin 22 Vitronectin Progesterone Estradiol Growth/differentiation factor 15 and Proprotein convertase subtilisin/kexin type 9 as diagnostic and prognostic biomarkers in renal injuries.

61. [20170336421](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE US - 23.11.2017

Int.Class [G01N 33/68](#) Appl.No 15660875 Applicant ASTUTE MEDICAL, INC. Inventor Joseph Anderberg

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Stanniocalcin-1, Antithrombin-III, Toll-like receptor 2, Triiodothyronine [T3], Thyroxine [T4], Extracellular matrix protein 1, Coagulation factor XIII A chain, Coagulation factor XIII B chain, Interleukin-17F, Interleukin-22, Vitronectin, Progesterone, Estradiol, Growth/differentiation factor 15, and Proprotein convertase subtilisin/kexin type 9 as diagnostic and prognostic biomarkers in renal injuries.

62. [2783213](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE EP - 01.10.2014

Int.Class [G01N 33/68](#) Appl.No 12851561 Applicant ASTUTE MEDICAL INC Inventor ANDERBERG JOSEPH

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Stanniocalcin- 1, Antithrombin-III, Toll-like receptor 2, Triiodothyronine [T3], Thyroxine [T4], Extracellular matrix protein 1, Coagulation factor XIII A chain, Coagulation factor XIII B chain, Interleukin-17F, Interleukin-22, Vitronectin, Progesterone, Estradiol, Growth/differentiation factor 15, and Proprotein convertase subtilisin/kexin type 9 as diagnostic and prognostic biomarkers in renal injuries.

63. [20140315752](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE US - 23.10.2014

Int.Class [G01N 33/68](#) Appl.No 14359910 Applicant ASTUTE MEDICAL, INC. Inventor Anderberg Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Stanniocalcin-1, Antithrombin-III, Toll-like receptor 2, Triiodothyronine [T3], Thyroxine [T4], Extracellular matrix protein 1, Coagulation factor XIII A chain, Coagulation factor XIII B chain, Interleukin-17F, Interleukin-22, Vitronectin, Progesterone, Estradiol, Growth/differentiation factor 15, and Proprotein convertase subtilisin/kexin type 9 as diagnostic and prognostic biomarkers in renal injuries.

64. [2856399](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE CA - 30.05.2013

Int.Class [G01N 33/48](#) Appl.No 2856399 Applicant ASTUTE MEDICAL, INC. Inventor



The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Stanniocalcin- 1, Antithrombin-III, Toll-like receptor 2, Triiodothyronine (T3), Thyroxine (T4), Extracellular matrix protein 1, Coagulation factor XIII A chain, Coagulation factor XIII B chain, Interleukin-17F, Interleukin-22, Vitronectin, Progesterone, Estradiol, Growth/differentiation factor 15, and Proprotein convertase subtilisin/kexin type 9 as diagnostic and prognostic biomarkers in renal injuries.

65. [625725](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE NZ - 30.09.2016

Int.Class [G01N 33/53](#) Appl.No 625725 Applicant ASTUTE MEDICAL, INC. Inventor ANDERBERG, Joseph

A method for evaluating renal status in a subject, comprises performing one or more assays configured to detect Growth/differentiation factor 15 (GDF-15) in a body fluid sample obtained from the subject to provide an assay result; and correlating the assay result(s) to the renal status of the subject. The correlation step comprises correlating the assay result(s) to one or more of diagnosis, risk stratification, prognosis, classifying and monitoring of the renal status of the subject.

66. [MX/A/2011/005379](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE MX - 28.07.2011

Int.Class [C12Q 1/68](#) Appl.No MX/a/2011/005379 Applicant ASTUTE MEDICAL, INC.\* Inventor ANDERBERG, Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Epidermal growth factor, Complement C3, Interleukin-4, Interleukin- 1 alpha, Tubulointerstitial nephritis antigen, Transforming growth factor beta-1, Bone morphogenetic protein 7, Osteopontin, Netrin-1, and Growth-regulated alpha protein as diagnostic and prognostic biomarkers in renal injuries.

67. [2743253](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE CA - 27.05.2010

Int.Class [G01N 33/68](#) Appl.No 2743253 Applicant ASTUTE MEDICAL, INC. Inventor ANDERBERG, JOSEPH

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Epidermal growth factor, Complement C3, Interleukin-4, Interleukin- 1 alpha, Tubulointerstitial nephritis antigen, Transforming growth factor beta-1, Bone morphogenetic protein 7, Osteopontin, Netrin-1, and Growth-regulated alpha protein as diagnostic and prognostic biomarkers in renal injuries.

68. [20110229915](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE US - 22.09.2011

Int.Class [G01N 33/566](#) Appl.No 13130474 Applicant ASTUTE MEDICAL, INC. Inventor Anderberg Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Epidermal growth factor, Complement C3, Interleukin-4, Interleukin-1 alpha, Tubulointerstitial nephritis antigen, Transforming growth factor beta-1, Bone morphogenetic protein 7, Osteopontin, Netrin-1, and Growth-regulated alpha protein as diagnostic and prognostic biomarkers in renal injuries.

69. [2364370](#) METHODS FOR PROGNOSIS OF ACUTE RENAL FAILURE EP - 14.09.2011

Int.Class [C12Q 1/68](#) Appl.No 09828325 Applicant ASTUTE MEDICAL INC Inventor ANDERBERG JOSEPH

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Epidermal growth factor, Complement C3, Interleukin-4, Interleukin- 1 alpha, Tubulointerstitial nephritis antigen, Transforming growth factor beta-1, Bone morphogenetic protein 7, Osteopontin, Netrin-1, and Growth-regulated alpha protein as diagnostic and prognostic biomarkers in renal injuries.

70. [WO/2013/078253](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE WO - 30.05.2013

Int.Class [G01N 33/53](#) Appl.No PCT/US2012/066152 Applicant ASTUTE MEDICAL, INC. Inventor ANDERBERG, Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Stanniocalcin- 1, Antithrombin-III, Toll-like receptor 2, Triiodothyronine (T3), Thyroxine (T4), Extracellular matrix protein 1, Coagulation factor XIII A chain, Coagulation factor XIII B chain, Interleukin-17F, Interleukin-22, Vitronectin, Progesterone, Estradiol, Growth/differentiation factor 15, and Proprotein convertase subtilisin/kexin type 9 as diagnostic and prognostic biomarkers in renal injuries.

71. [2707524](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE EP - 19.03.2014

Int.Class [C40B 30/04](#) Appl.No 12781602 Applicant ASTUTE MEDICAL INC Inventor ANDERBERG JOSEPH

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Transforming growth factor beta-1, Transforming growth factor beta-2, Transforming growth factor beta-3, and Interleukin-1 receptor-like 1 as diagnostic and prognostic biomarkers in renal injuries.

72. [20170234867](#) QUANTITATIVE LATERAL FLOW ASSAY

US - 17.08.2017



Int.Class [G01N 33/558](#) Appl.No 15444178 Applicant Astute Medical, Inc. Inventor Joseph ANDERBERG

The present invention relates to devices, kits, instruments and methods for quantitatively detecting multiple analytes in a sample. More specifically, the present invention relates to devices, kits, instruments and methods for quantitatively detecting multiple analytes with desired or targeted precision, and the uses thereof.

73. [20170363647](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF STROKE OR OTHER CEREBRAL INJURY US - 21.12.2017

Int.Class [G01N 33/68](#) Appl.No 15676754 Applicant ASTUTE MEDICAL, INC. Inventor Paul McPherson

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in stroke patients and in patients at risk for stroke. In particular, the invention relates to using assays that detect one or more biomarkers as diagnostic and prognostic biomarker assays in such patients.

74. [2841945](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF STROKE OR OTHER CEREBRAL INJURY EP - 04.03.2015

Int.Class [G01N 33/68](#) Appl.No 13782208 Applicant ASTUTE MEDICAL INC Inventor ANDERBERG JOSEPH

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in stroke patients and in patients at risk for stroke. In particular, the invention relates to using assays that detect one or more biomarkers as diagnostic and prognostic biomarker assays in such patients.

75. [20150119269](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF STROKE OR OTHER CEREBRAL INJURY US - 30.04.2015

Int.Class [G01N 33/68](#) Appl.No 14396377 Applicant ASTUTE MEDICAL, INC. Inventor Joseph Anderberg

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in stroke patients and in patients at risk for stroke. In particular, the invention relates to using assays that detect one or more biomarkers as diagnostic and prognostic biomarker assays in such patients.

76. [2010315008](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE AU - 31.05.2012

Int.Class [G01N 33/53](#) Appl.No 2010315008 Applicant Astute Medical, Inc. Inventor Anderberg, Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Cathepsin B, Renin, Dipeptidyl Peptidase IV, Neprilysin, Beta-2- microglobulin, Carbonic anhydrase IX, and C-X-C motif chemokine 2 as diagnostic and prognostic biomarkers in renal injuries.

77. [2014277715](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE AU - 22.01.2015

Int.Class [G01N 33/53](#) Appl.No 2014277715 Applicant Astute Medical, Inc. Inventor Anderberg, Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Cathepsin B, Renin, Dipeptidyl Peptidase IV, Neprilysin, Beta-2 microglobulin, Carbonic anhydrase IX, and C-X-C motif chemokine 2 as diagnostic and prognostic biomarkers in renal injuries.

78. [20220113319](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE US - 14.04.2022

Int.Class [G01N 33/68](#) Appl.No 17558443 Applicant ASTUTE MEDICAL, INC. Inventor JOSEPH ANDERBERG

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect Chitinase-3-like protein 1 as diagnostic and prognostic biomarker assays in renal injuries.

79. [20160313350](#) METHODS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE USING TREFOIL FACTOR 3 FAILURE US - 27.10.2016

Int.Class [G01N 33/68](#) Appl.No 15137982 Applicant ASTUTE MEDICAL, INC. Inventor Joseph Anderberg

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect Trefoil factor 3 as diagnostic and prognostic biomarker assays in renal injuries.

80. [2661620](#) METHOD AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE EP - 13.11.2013

Int.Class [G01N 33/68](#) Appl.No 12732159 Applicant ASTUTE MEDICAL INC Inventor ANDERBERG JOSEPH

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect Trefoil factor 3 as diagnostic and prognostic biomarker assays in renal injuries.



81. [20170363642](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE US - 21.12.2017

Int.Class [G01N 33/50](#) Appl.No 15537361 Applicant ASTUTE MEDICAL, INC. Inventor Joseph Anderberg

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect Chitinase-3-like protein 1 as diagnostic and prognostic biomarker assays in renal injuries.

82. [20200064360](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE US - 27.02.2020

Int.Class [G01N 33/50](#) Appl.No 16679486 Applicant ASTUTE MEDICAL, INC. Inventor Joseph Anderberg

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect Chitinase-3-like protein 1 as diagnostic and prognostic biomarker assays in renal injuries.

83. [628085](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE NZ - 24.12.2015

Int.Class [G01N 33/53](#) Appl.No 628085 Applicant Astute Medical, Inc. Inventor ANDERBERG, Joseph

Disclosed is an ex vivo method for evaluating renal status in a subject, the method comprising: performing one or more assays configured to detect the biomarker soluble Neprilysin in a body fluid sample obtained previously from the subject, determining one or more assay result(s) each assay result comprising a measured concentration of soluble Neprilysin; and correlating the assay result(s) to the renal status of the subject, the correlating comprising comparing a measured concentration of soluble Neprilysin to a threshold concentration of soluble Neprilysin and assigning a likelihood or non-likelihood of an event occurring or having occurred when the measured concentration varies from the threshold. Also disclosed is a use of an antibody in a method performed ex vivo in determining renal status of a subject, wherein the antibody binds specifically to soluble Neprilysin, wherein the method is performed on a body fluid sample obtained previously from the subject.

84. [599773](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE NZ - 26.09.2014

Int.Class [G01N 33/53](#) Appl.No 599773 Applicant Astute Medical, Inc. Inventor ANDERBERG, Joseph

Disclosed is an ex vivo method for evaluating renal status in a subject, said method comprising: performing one or more assays on a body fluid sample obtained previously from the subject, wherein the one or more assays comprise an assay configured to detect C-X-C motif chemokine 2 [CXC-2] wherein performing said assay(s) provides an assay result comprising a measured concentration of the CXC-2 in the body fluid sample; comparing a measured concentration of the CXC-2 in the body fluid sample to a threshold concentration of CXC-2; and correlating the assay result to the renal status of the subject comprising: (i) assigning a diagnosis that reduced or worsening renal function or an event an event associated with reduced or worsening renal function has occurred, or assigning a risk or likelihood that reduced or worsening renal function or an event an event associated with reduced or worsening renal function is likely to occur in future, when the measured concentration is above the threshold concentration; or (ii) assigning a diagnosis that reduced or worsening renal function or an event an event associated with reduced or worsening renal function has not occurred, or assigning a risk or likelihood that reduced or worsening renal function or an event an event associated with reduced or worsening renal function is not likely to occur in future, when the measured concentration is below the threshold concentration. Also disclosed is a use of an antibody or antibody fragment in a method performed ex vivo in evaluating renal status of a subject, wherein the antibody or antibody fragment binds specifically to C-X-C motif chemokine 2 [CXC-2] or an epitope thereof, and wherein said method is performed on a body fluid sample obtained previously from the subject.

85. [104793000](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE CN - 22.07.2015

Int.Class [G01N 33/68](#) Appl.No 201510191800.0 Applicant ASTUTE MEDICAL INC Inventor ANDERBERG JOSEPH

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Cathepsin B, Renin, Dipeptidyl Peptidase IV, Neprilysin, Beta-2- microglobulin, Carbonic anhydrase IX, and C-X-C motif chemokine 2 as diagnostic and prognostic biomarkers in renal injuries.

86. [2779902](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE CA - 12.05.2011

Int.Class [G01N 33/48](#) Appl.No 2779902 Applicant ASTUTE MEDICAL, INC. Inventor ANDERBERG, JOSEPH

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Cathepsin B, Renin, Dipeptidyl Peptidase IV, Neprilysin, Beta-2- microglobulin, Carbonic anhydrase IX, and C-X-C motif chemokine 2 as diagnostic and prognostic biomarkers in renal injuries.

87. [2496942](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE EP - 12.09.2012

Int.Class [G01N 33/68](#) Appl.No 10829198 Applicant ASTUTE MEDICAL INC Inventor ANDERBERG JOSEPH

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Cathepsin B, Renin, Dipeptidyl Peptidase IV, Neprilysin, Beta-2- microglobulin, Carbonic anhydrase IX, and C-X-C motif chemokine 2 as diagnostic and prognostic biomarkers in renal injuries.

88. [102725635](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE CN - 10.10.2012

Int.Class [G01N 33/53](#) Appl.No 20108006026.1 Applicant Astute Medical, Inc. Inventor Anderberg Joseph



The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Cathepsin B, Renin, Dipeptidyl Peptidase IV, Nephilysin, Beta-2- microglobulin, Carbonic anhydrase IX, and C-X-C motif chemokine 2 as diagnostic and prognostic biomarkers in renal injuries.

89. [1110/MUMNP/2012](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE IN - 04.10.2013

Int.Class [G01N 33/53](#) Appl.No 1110/MUMNP/2012 Applicant ASTUTE MEDICAL INC Inventor ANDERBERG Joseph

The present invention relates to methods and compositions for monitoring diagnosis prognosis and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Cathepsin B Renin Dipeptidyl Peptidase IV Nephilysin Beta-2-microglobulin Carbonic anhydrase IX and C-X-C motif chemokine 2 as diagnostic and prognostic biomarkers in renal injuries.

90. [WO/2016/100912](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE WO - 23.06.2016

Int.Class [A61K 38/17](#) Appl.No PCT/US2015/066864 Applicant ASTUTE MEDICAL, INC. Inventor ANDERBERG, Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect Chitinase-3-like protein 1 as diagnostic and prognostic biomarker assays in renal injuries.

91. [WO/2013/163345](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF STROKE OR OTHER CEREBRAL INJURY WO - 31.10.2013

Int.Class [G01N 33/53](#) Appl.No PCT/US2013/038067 Applicant ASTUTE MEDICAL, INC. Inventor ANDERBERG, Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in stroke patients and in patients at risk for stroke. In particular, the invention relates to using assays that detect one or more biomarkers as diagnostic and prognostic biomarker assays in such patients.

92. [2531620](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE EP - 12.12.2012

Int.Class [C12Q 1/68](#) Appl.No 11740468 Applicant ASTUTE MEDICAL INC Inventor ANDERBERG JOSEPH

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Coagulation factor VII, CA 19-9, Insulin-like growth factor-binding protein 7, C-X-C motif chemokine 6, and C-C motif chemokine 13 as diagnostic and prognostic biomarkers in renal injuries.

93. [2012008956](#) METODOS Y COMPOSICIONES PARA DIAGNOSTICO Y PROGNOSIS DE LESION RENAL Y FALLA RENAL. MX - 07.09.2012

Int.Class [C12Q 1/68](#) Appl.No 2012008956 Applicant ASTUTE MEDICAL, INC. Inventor ANDERBERG, Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Coagulation factor VII, CA 19-9, Insulin-like growth factor-binding protein 7, C-X-C motif chemokine 6, and C-C motif chemokine 13 as diagnostic and prognostic biomarkers in renal injuries.

94. [1886/MUMNP/2012](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE IN - 29.11.2013

Int.Class [C12Q 1/68](#) Appl.No 1886/MUMNP/2012 Applicant ASTUTE MEDICAL INC. Inventor ANDERBERG Joseph

The present invention relates to methods and compositions for monitoring diagnosis prognosis and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Coagulation factor VII CA19-9 Insulin-like growth factor-binding protein 7 C-X-C motif chemokine 6 and C-C motif chemokine 13 as diagnostic and prognostic biomarkers in renal injuries.

95. [619835](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE NZ - 04.05.2016

Int.Class [G01N 33/50](#) Appl.No 619835 Applicant ASTUTE MEDICAL, INC. Inventor ANDERBERG, Joseph

96. [54879](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE RS - 31.10.2016

Int.Class [C12Q 1/68](#) Appl.No 20160473 Applicant ASTUTE MEDICAL INC Inventor ANDERBERG JOSEPH

Metod za procenu statusa bubrega kod subjekta, naznačen time što uključuje: sprovođenje jedne ili više analiza uobičenih da detektuju jedan ili više biomarkera koji uključuju protein 7 vezujući insulinu sličnog faktora rasta u uzorku telesne tečnosti dobijene od subjekta da se obezbedi rezultat analize; i uključuje korelaciju rezultata analize sa statusom bubrega kod subjekta, pri čemu navedena faza korelacije obuhvata procenu mogućnosti da na osnovu rezultata analize u budućnosti dođe do jedne ili više promena u statusu bubrega kod subjekta. Prijava sadrži još 16 patentnih zahteva.

97. [71/MUMNP/2014](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE IN - 21.11.2014



Int.Class [C12Q 1/68](#) Appl.No 71/MUMNP/2014 Applicant ASTUTE MEDICAL INC. Inventor ANDERBERG Joseph

The present invention relates to methods and compositions for monitoring diagnosis prognosis and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Heat shock protein beta 1 WAP four disulfide core domain protein 2 Choriogonadotropin subunit beta Placenta growth factor and Mitochondrial 60 kDa heat shock protein as diagnostic and prognostic biomarkers in renal injuries.

98. [601590](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE NZ - 31.10.2014

Int.Class [C12Q 1/68](#) Appl.No 601590 Applicant Astute Medical, Inc. Inventor ANDERBERG, Joseph

Disclosed is a method for evaluating renal status in a subject, comprising: performing one or more assays configured to detect Insulin-like growth factor-binding protein 7 (IGFBP7), on a body fluid sample obtained from the subject; and correlating an assay result(s) to a risk of reduced renal function, injury to renal function, or acute renal failure in the subject, wherein said risk is a risk determined for a period 72 hours or less after said body fluid sample was obtained.

99. [700695](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE NZ - 27.05.2016

Int.Class [C12Q 1/68](#) Appl.No 700695 Applicant Astute Medical, Inc. Inventor ANDERBERG, Joseph

Disclosed is a method for evaluating renal status in a subject, comprising: performing one or more assays configured to detect C-X-C motif chemokine 6 on a body fluid sample obtained from the subject; and correlating the assay result(s) to the renal status of the subject, said correlating comprising comparing a measured concentration of C-X-C motif chemokine 6 to a threshold concentration of C-X-C motif chemokine 6, wherein a concentration of C-X-C motif chemokine 6 above or at the threshold concentration indicates a worse renal status than a concentration of C-X-C motif chemokine 6 below the threshold concentration.

100. [2015200547](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE AU - 19.02.2015

Int.Class [C12Q 1/68](#) Appl.No 2015200547 Applicant Astute Medical, Inc. Inventor Anderberg, Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Coagulation factor VII, CA 19-9, Insulin-like growth factor-binding protein 7, C-X-C motif chemokine 6, and C-C motif chemokine 13 as diagnostic and prognostic biomarkers in renal injuries.

101. [2666872](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE EP - 27.11.2013

Int.Class [C12Q 1/68](#) Appl.No 13177829 Applicant ASTUTE MEDICAL INC Inventor ANDERBERG JOSEPH

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect one or more kidney injury markers comprising Insulin-like growth factor-binding protein 7.

102. [20160097779](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE US - 07.04.2016

Int.Class [G01N 33/68](#) Appl.No 14964410 Applicant ASTUTE MEDICAL, INC. Inventor Joseph ANDERBERG

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Heat shock protein beta-1, WAP four-disulfide core domain protein 2, Choriogonadotropin subunit beta, Placenta growth factor, and Mitochondrial 60 kDa heat shock protein as diagnostic and prognostic biomarkers in renal injuries.

103. [3489688](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE EP - 29.05.2019

Int.Class [G01N 33/68](#) Appl.No 18189709 Applicant ASTUTE MEDICAL INC Inventor ANDERBERG JOSEPH

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of C-C Motif chemokine 24, Cancer antigen CA 15-3, C-C Motif chemokine 18, , Cathepsin D, C-X-C Motif chemokine 13, C-C motif chemokine 8, Interleukin-2 receptor alpha chain, Insulin-like growth factor-binding protein 3, Interleukin-11, Matrix Metalloproteinase-8, Transforming growth factor alpha, IgG1, and IgG2 as diagnostic and prognostic biomarkers in renal injuries.

104. [703068](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE NZ - 21.06.2016

Int.Class [G01N 33/48](#) Appl.No 703068 Applicant ASTUTE MEDICAL, INC. Inventor ANDERBERG, Joseph

105. [20170254816](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE US - 07.09.2017

Int.Class [G01N 33/68](#) Appl.No 15604573 Applicant ASTUTE MEDICAL, INC. Inventor Joseph Anderberg

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Cancer antigen CA 15-3, C-C Motif chemokine 18, C-C Motif chemokine 24, Cathepsin D, C-X-C Motif chemokine



13, C-C motif chemokine 8, Interleukin-2 receptor alpha chain, Insulin-like growth factor-binding protein 3, Interleukin-11, Matrix Metalloproteinase-8, Transforming growth factor alpha, IgG1, and IgG2 as diagnostic and prognostic biomarkers in renal injuries.

106. [2011269774](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE AU - 07.02.2013

Int.Class [G01N 33/48](#) Appl.No 2011269774 Applicant Astute Medical, Inc. Inventor Anderberg, Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Cancer antigen CA 15-3, C-C Motif chemokine 18, C-C Motif chemokine 24, Cathepsin D, C-X-C Motif chemokine 13, C-C motif chemokine 8, Interleukin-2 receptor alpha chain, Insulin-like growth factor-binding protein 3, Interleukin-11, Matrix Metalloproteinase-8, Transforming growth factor alpha, IgG1, and IgG2 as diagnostic and prognostic biomarkers in renal injuries.

107. [606124](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE NZ - 29.05.2015

Int.Class [G01N 33/48](#) Appl.No 606124 Applicant ASTUTE MEDICAL, INC. Inventor ANDERBERG, Joseph

Disclosed is a method for evaluating renal status in a subject ex vivo, comprising: -performing one or more assays configured to detect C-X-C Motif chemokine 13 in a body fluid sample obtained previously from the subject; -determining an assay result(s) comprising a measured level of the C-X-C Motif chemokine 13; and -correlating an assay result(s) to the renal status of the subject said correlating comprising comparing a measured concentration of the C-X-C Motif chemokine 13 to a threshold concentration of C-X-C Motif chemokine 13 and assigning a likelihood or non-likelihood of an event occurring or having occurred when the measured concentration varies from the threshold.

108. [2808/MUMNP/2012](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE IN - 31.01.2014

Int.Class [G01N 33/48](#) Appl.No 2808/MUMNP/2012 Applicant ASTUTE MEDICAL, INC. Inventor ANDERBERG, Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Cancer antigen CA 15-3, C-C Motif chemokine 18, C-C Motif chemokine 24, Cathepsin D, C-X-C Motif chemokine 13, C-C motif chemokine 8, Interleukin-2 receptor alpha chain, Insulin-like growth factor-binding protein 3, Interleukin-11, Matrix Metalloproteinase-8, Transforming growth factor alpha, IgG1, and IgG2 as diagnostic and prognostic biomarkers in renal injuries.

109. [366653](#) METODOS Y COMPOSICIONES PARA DIAGNOSIS Y PROGNOSIS DE LESION RENAL Y FALLA RENAL. MX - 17.07.2019

Int.Class [G01N 33/68](#) Appl.No 2016010109 Applicant ASTUTE MEDICAL, INC. Inventor ANDERBERG, Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Coagulation factor VII, CA 19-9, Insulin-like growth factor-binding protein 7, C-X-C motif chemokine 6, and C-C motif chemokine 13 as diagnostic and prognostic biomarkers in renal injuries.

110. [112012019542](#) "MÉTODO PARA AVALIAR O ESTADO RENAL EM UM INDIVÍDUO, MEDIÇÃO DE UM OU MAIS BIOMARCADORES, E, KIT" BR - 27.03.2018

Int.Class [C12Q 1](#) Appl.No 112012019542 Applicant Astute Medical, Inc. Inventor James Patrick Kampf

método para avaliar o estado renal em um indivíduo, medição de um ou mais biomarcadores, e, kit. a presente invenção diz respeito a métodos e composições para monitorar, diagnosticar, prognosticar e determinação de regimes de tratamento em indivíduos que sofrem de ou suspeitos de ter um dano renal. em particular, a invenção diz respeito ao uso de um ou mais ensaios configurados para a detecção de um marcador de dano renal selecionado do grupo que consiste do grupo que consiste de fator de coagulação vii, ca 19-9, proteína de ligação do fator de desenvolvimento semelhante a insulina 7, quimiocina de motivo c-x-c 6 e quimiocina de motivo c-c 13 como biomarcadores de diagnóstico e prognóstico em danos renais.

111. [2585826](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE EP - 01.05.2013

Int.Class [G01N 33/48](#) Appl.No 11798515 Applicant ASTUTE MEDICAL INC Inventor ANDERBERG JOSEPH

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Cancer antigen CA 15-3, C-C Motif chemokine 18, C-C Motif chemokine 24, Cathepsin D, C-X-C Motif chemokine 13, C-C motif chemokine 8, Interleukin-2 receptor alpha chain, Insulin-like growth factor-binding protein 3, Interleukin-11, Matrix Metalloproteinase-8, Transforming growth factor alpha, IgG1, and IgG2 as diagnostic and prognostic biomarkers in renal injuries.

112. [2803500](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE CA - 29.12.2011

Int.Class [G01N 33/68](#) Appl.No 2803500 Applicant ASTUTE MEDICAL, INC. Inventor ANDERBERG, JOSEPH

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Cancer antigen CA 15-3, C-C Motif chemokine 18, C-C Motif chemokine 24, Cathepsin D, C-X-C Motif chemokine 13, C-C motif chemokine 8, Interleukin-2 receptor alpha chain, Insulin-like growth factor-binding protein 3, Interleukin-11, Matrix Metalloproteinase-8, Transforming growth factor alpha, IgG1, and IgG2 as diagnostic and prognostic biomarkers in renal injuries.



113. **2013000220** METODOS Y COMPOSICIONES PARA DIAGNÓSTICO Y PRONÓSTICO DE LESIÓN RENAL E INSUFICIENCIA RENAL. MX - 22.03.2013

Int.Class **G01N 33/48** Appl.No 2013000220 Applicant **ASTUTE MEDICAL, INC.** Inventor **ANDERBERG, Joseph**

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Cancer antigen CA 15-3, C-C Motif chemokine 18, C-C Motif chemokine 24, Cathepsin D, C-X-C Motif chemokine 13, C-C motif chemokine 8, Interleukin-2 receptor alpha chain, Insulin-like growth factor-binding protein 3, Interleukin-11, Matrix Metalloproteinase-8, Transforming growth factor alpha, IgG1, and IgG2 as diagnostic and prognostic biomarkers in renal injuries.

114. **2899545** METHODS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE EP - 29.07.2015

Int.Class **G01N 33/68** Appl.No 15151607 Applicant **ASTUTE MEDICAL INC** Inventor **ANDERBERG JOSEPH**

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of C-C Motif chemokine 24, and optionally Cancer antigen CA 15-3, C-C Motif chemokine 18, , Cathepsin D, C-X-C Motif chemokine 13, C-C motif chemokine 8, Interleukin-2 receptor alpha chain, Insulin-like growth factor-binding protein 3, Interleukin-11, Matrix Metalloproteinase-8, Transforming growth factor alpha, IgG1, and IgG2 as diagnostic and prognostic biomarkers in renal injuries.

115. **2011213684** METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE AU - 23.08.2012

Int.Class **C12Q 1/68** Appl.No 2011213684 Applicant **Astute Medical, Inc.** Inventor **Anderberg, Joseph**

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Coagulation factor VII, CA 19-9, Insulin-like growth factor-binding protein 7, C-X-C motif chemokine 6, and C-C motif chemokine 13 as diagnostic and prognostic biomarkers in renal injuries.

116. **2012282918** METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE AU - 06.02.2014

Int.Class **G01N 33/50** Appl.No 2012282918 Applicant **Astute Medical, Inc.** Inventor **Anderberg, Joseph**

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Heat shock protein beta- 1, WAP four-disulfide core domain protein 2, Choriogonadotropin subunit beta, Placenta growth factor, and Mitochondrial 60 kDa heat shock protein as diagnostic and prognostic biomarkers in renal injuries.

117. **2841880** METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE CA - 17.01.2013

Int.Class **G01N 33/48** Appl.No 2841880 Applicant **ASTUTE MEDICAL, INC.** Inventor

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Heat shock protein beta- 1, WAP four-disulfide core domain protein 2, Choriogonadotropin subunit beta, Placenta growth factor, and Mitochondrial 60 kDa heat shock protein as diagnostic and prognostic biomarkers in renal injuries.

118. **2014000283** METODOS Y COMPOSICIONES PARA DIAGNÓSTICO Y PRONÓSTICO DE LESIÓN E INSUFICIENCIA RENAL. MX - 01.05.2014

Int.Class **G01N 33/50** Appl.No 2014000283 Applicant **ASTUTE MEDICAL, INC.** Inventor **ANDERBERG, Joseph**

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Heat shock protein beta- 1, WAP four-disulfide core domain protein 2, Choriogonadotropin subunit beta, Placenta growth factor, and Mitochondrial 60 kDa heat shock protein as diagnostic and prognostic biomarkers in renal injuries.

119. **2729803** METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE EP - 14.05.2014

Int.Class **G01N 33/50** Appl.No 12810709 Applicant **ASTUTE MEDICAL INC** Inventor **ANDERBERG JOSEPH**

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Heat shock protein beta- 1, WAP four-disulfide core domain protein 2, Choriogonadotropin subunit beta, Placenta growth factor, and Mitochondrial 60 kDa heat shock protein as diagnostic and prognostic biomarkers in renal injuries.

120. **2788826** METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE CA - 11.08.2011

Int.Class **G01N 33/48** Appl.No 2788826 Applicant **ASTUTE MEDICAL, INC.** Inventor **ANDERBERG, JOSEPH**

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Coagulation factor VII, CA 19-9, Insulin-like growth factor-binding protein 7, C-X-C motif chemokine 6, and C-C motif chemokine 13 as diagnostic and prognostic biomarkers in renal injuries.



121. [20170315134](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE US - 02.11.2017

Int.Class [G01N 33/68](#) Appl.No 15526271 Applicant ASTUTE MEDICAL, INC. Inventor Joseph Anderberg

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect Interleukin-18-binding protein as diagnostic and prognostic biomarker assays in renal injuries.

122. [107003325](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE CN - 01.08.2017

Int.Class [G01N 33/68](#) Appl.No 201580065880.3 Applicant ASTUTE MEDICAL INC. Inventor ANDERBERG JOSEPH

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect Interleukin-18 -binding protein as diagnostic and prognostic biomarker assays in renal injuries.

123. [WO/2016/077484](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE WO - 19.05.2016

Int.Class [G01N 33/68](#) Appl.No PCT/US2015/060204 Applicant ASTUTE MEDICAL, INC. Inventor ANDERBERG, Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect Interleukin-18 -binding protein as diagnostic and prognostic biomarker assays in renal injuries.

124. [20190339289](#) METHODS AND COMPOSITIONS FOR EVALUATION AND TREATMENT OF RENAL INJURY AND RENAL FAILURE BASED ON C-C MOTIF CHEMOKINE LIGAND 14 MEASUREMENT US - 07.11.2019

Int.Class [G01N 33/68](#) Appl.No 16475326 Applicant ASTUTE MEDICAL, INC. Inventor James Patrick Kampf

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect C-C motif chemokine 14 as diagnostic and prognostic biomarker assays in renal injuries.

125. [WO/2018/132702](#) METHODS AND COMPOSITIONS FOR EVALUATION AND TREATMENT OF RENAL INJURY AND RENAL FAILURE BASED ON C-C MOTIF CHEMOKINE LIGAND 14 MEASUREMENT WO - 19.07.2018

Int.Class [G01N 33/48](#) Appl.No PCT/US2018/013561 Applicant ASTUTE MEDICAL, INC. Inventor KAMPF, James, Patrick

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect C-C motif chemokine 14 as diagnostic and prognostic biomarker assays in renal injuries.

126. [2019008260](#) METODOS Y COMPOSICIONES PARA LA EVALUACION Y TRATAMIENTO DE LESION RENAL E INSUFICIENCIA RENAL CON BASE EN LA MEDICION DEL LIGANDO 14 DE QUIMIOCINA DE LA PORCION C-C. MX - 27.01.2020

Int.Class [G01N 33/48](#) Appl.No 2019008260 Applicant ASTUTE MEDICAL, INC. Inventor Paul MCPHERSON

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect C-C motif chemokine 14 as diagnostic and prognostic biomarker assays in renal injuries.

127. [703256](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PRONOSIS OF RENAL INJURY AND RENAL FAILURE NZ - 21.07.2016

Int.Class [G01N 33/543](#) Appl.No 703256 Applicant ASTUTE MEDICAL, INC. Inventor ANDERBERG, Joseph

128. [2805238](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE CA - 19.01.2012

Int.Class [G01N 33/68](#) Appl.No 2805238 Applicant ASTUTE MEDICAL, INC. Inventor ANDERBERG, JOSEPH

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Alpha-2-HS-glycoprotein, Interleukin-9, Leukemia inhibitory factor, Macrophage colony-stimulating factor 1, Prolactin, and Stromal cell-derived factor 12 as diagnostic and prognostic biomarkers in renal injuries.

129. [2011279712](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE AU - 21.02.2013

Int.Class [G01N 33/53](#) Appl.No 2011279712 Applicant Astute Medical, Inc. Inventor Anderberg, Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Alpha-2-HS-glycoprotein, Interleukin-9, Leukemia inhibitory factor, Macrophage colony-stimulating factor 1, Prolactin, and Stromal cell-derived factor 12 as diagnostic and prognostic biomarkers in renal injuries.



130. [96/MUMNP/2013](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE IN - 14.02.2014

Int.Class [G01N 33/543](#) Appl.No 96/MUMNP/2013 Applicant ASTUTE MEDICAL INC. Inventor ANDERBERG Joseph

The present invention relates to methods and compositions for monitoring diagnosis prognosis and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Alpha 2 HS glycoprotein Interleukin 9 Leukemia inhibitory factor Macrophage colony stimulating factor 1 Prolactin and Stromal cell derived factor 12 as diagnostic and prognostic biomarkers in renal injuries.

131. [606436](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE NZ - 30.10.2015

Int.Class [G01N 33/543](#) Appl.No 606436 Applicant ASTUTE MEDICAL, INC. Inventor ANDERBERG, Joseph

A method for evaluating acute renal status in a subject, comprising: performing one or more binding assays configured to detect Alpha-2-HS-glycoprotein in a body fluid sample obtained from the subject; and correlating the assay result(s) to the renal status of the subject, wherein said correlation step comprises correlating the assay result(s) to one or more of risk stratification, prognosis, classifying and monitoring of the renal status of the subject, wherein said one or more binding assays comprises contacting the body fluid with one or more binding reagents that specifically bind to Alpha-2-HS-glycoprotein, and wherein if the body fluid sample is a urine sample, the urine sample is not an exosomal fraction.

132. [2593794](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE EP - 22.05.2013

Int.Class [G01N 33/68](#) Appl.No 11807169 Applicant ASTUTE MEDICAL INC Inventor ANDERBERG JOSEPH

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Alpha-2-HS-glycoprotein, Interleukin-9, Leukemia inhibitory factor, Macrophage colony-stimulating factor 1, Prolactin, and Stromal cell-derived factor 12 as diagnostic and prognostic biomarkers in renal injuries.

133. [2014270083](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE AU - 18.12.2014

Int.Class [G01N 33/48](#) Appl.No 2014270083 Applicant Astute Medical, Inc. Inventor Anderberg, Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a plurality of assays, one or more of which is configured to detect a kidney injury marker selected from the group consisting of metalloproteinase inhibitor 2, soluble oxidized low-density lipoprotein receptor 1, interleukin-2, von Willebrand factor, granulocyte-macrophage colony-stimulating factor, tumor necrosis factor receptor superfamily member 11 B, neutrophil elastase, interleukin-1 beta, heart-type fatty acid-binding protein, beta-2-glycoprotein 1, soluble CD40 ligand, coagulation factor VII, C-C motif chemokine 2, IgM, CA 19-9, IL-10, TNF-a, and myoglobin as diagnostic and prognostic biomarkers in renal injuries.

134. [746/MUMNP/2012](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE IN - 01.02.2013

Int.Class [A61K 31/00](#) Appl.No 746/MUMNP/2012 Applicant ASTUTE MEDICAL INC. Inventor ANDERBERG Joseph

The present invention relates to methods and compositions for monitoring diagnosis prognosis and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular the invention relates to using a plurality of assays one or more of which is configured to detect a kidney injury marker selected from the group consisting of metalloproteinase inhibitor 2 soluble oxidized low-density lipoprotein receptor 1 interleukin-2 von Willebrand factor granulocyte-macrophage colony-stimulating factor tumor necrosis factor receptor superfamily member 11B neutrophil elastase interleukin-1 beta heart-type fatty acid-binding protein beta-2-glycoprotein 1 soluble CD40 ligand coagulation factor VII C-C motif chemokine 2 IgM CA 19-9 IL-10 TNF-a and myoglobin as diagnostic and prognostic biomarkers in renal injuries.

135. [599105](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE NZ - 29.08.2014

Int.Class [G01N 33/48](#) Appl.No 599105 Applicant Astute Medical, Inc. Inventor ANDERBERG, Joseph

Disclosed is a method for evaluating renal status in a subject, said method comprising: - performing a plurality of assays configured to detect both of the proteins tissue metalloproteinase inhibitor-2 (TIMP-2) and tumour necrosis factor receptor superfamily member 11B (TNFRSF11B) in one or more body fluid samples obtained previously from the subject by contacting the body fluid sample(s) with molecules that bind to each of TIMP-2 and TNFRSF11B under conditions sufficient for such binding to occur; - determining a measured concentration of each of TIMP-2 and TNFRSF11B from the amounts of the molecules bound thereto in the body fluid sample(s); - combining the measured concentration of each of TIMP-2 and TNFRSF11B using a function that converts the assay results into a single composite result to thereby provide a combined concentration of TIMP-2 and TNFRSF11B for the subject; - comparing the combined concentration of TIMP-2 and TNFRSF11B for the subject to a threshold concentration; and - correlating the assay results to the renal status of the subject. Also disclosed is a combined use of antibodies or antibody fragments in a method performed ex vivo on one or more body fluid samples obtained previously from a subject in determining a present or future reduced renal function in the subject, wherein the antibodies or antibody fragments bind independently to: (i) TIMP-2 or an epitope thereof; and (ii) TNFRSF11B or an epitope thereof.

136. [723180](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE NZ - 08.03.2018

Int.Class [G01N 33/48](#) Appl.No 723180 Applicant Astute Medical, Inc. Inventor ANDERBERG, Joseph

137. [2480882](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE EP - 01.08.2012



## FAILURE

Int.Class [G01N 33/48](#) Appl.No 10818036 Applicant ASTUTE MEDICAL INC Inventor ANDERBERG JOSEPH

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a plurality of assays, one or more of which is configured to detect a kidney injury marker selected from the group consisting of metalloproteinase inhibitor 2, soluble oxidized low-density lipoprotein receptor 1, interleukin-2, von Willebrand factor, granulocyte-macrophage colony-stimulating factor, tumor necrosis factor receptor superfamily member HB, neutrophil elastase, interleukin-1 beta, heart-type fatty acid-binding protein, beta-2-glycoprotein 1, soluble CD40 ligand, coagulation factor VII, C-C motif chemokine 2, IgM, CA 19-9, IL-10, TNF- $\alpha$ , and myoglobin as diagnostic and prognostic biomarkers in renal injuries.

138. [630277](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE

NZ - 27.02.2015

Int.Class [G01N 33/48](#) Appl.No 630277 Applicant Astute Medical, Inc. Inventor ANDERBERG, Joseph

Disclosed is a method for evaluating renal status in a subject, comprising: - performing a plurality of assays configured to detect both of the proteins metalloproteinase inhibitor 2 and neutrophil elastase in one or more body fluid samples obtained previously from the subject by contacting the body fluid sample(s) with molecules that bind to each of metalloproteinase inhibitor 2 and neutrophil elastase under conditions sufficient for such binding to occur; - determining a measured concentration of each of metalloproteinase inhibitor 2 and neutrophil elastase from the amounts of the molecules bound thereto in the body fluid samples; - combining the measured concentration of each of metalloproteinase inhibitor 2 and neutrophil elastase using a function that converts the assay results into a single composite result to thereby provide a combined concentration of metalloproteinase inhibitor 2 and neutrophil elastase for the subject; - comparing the combined concentration of metalloproteinase inhibitor 2 and neutrophil elastase to a threshold combined concentration; and correlating the assay results to the renal status of the subject, said correlating comprising: (i) assigning a diagnosis that reduced or worsening renal function or an event an event associated with reduced or worsening renal function has occurred, or assigning a risk or likelihood that reduced or worsening renal function or an event an event associated with reduced or worsening renal function is likely to occur in future, when the combined concentration of metalloproteinase inhibitor 2 and neutrophil elastase is above the threshold concentration; or (ii) assigning a diagnosis that reduced or worsening renal function or an event an event associated with reduced or worsening renal function has not occurred, or assigning a risk or likelihood that reduced or worsening renal function or an event an event associated with reduced or worsening renal function is not likely to occur in future, when the combined concentration of metalloproteinase inhibitor 2 and neutrophil elastase is below the threshold concentration.

139. [619883](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE

NZ - 28.11.2014

Int.Class [G01N 33/48](#) Appl.No 619883 Applicant Astute Medical, Inc. Inventor ANDERBERG, Joseph

A method for evaluating renal status in a subject and a kit when used in the method are disclosed. The method comprises performing a plurality of assays configured to detect both of the proteins soluble oxidized low-density lipoprotein receptor 1 and neutrophil elastase in one or more body fluid samples obtained previously from the subject by contacting the body fluid sample(s) with molecules that bind to each of soluble oxidized low-density lipoprotein receptor 1 and neutrophil elastase under conditions sufficient for such binding to occur. A measured concentration is determined of each of soluble oxidized low-density lipoprotein receptor 1 and neutrophil elastase from the amounts of the molecules bound thereto in the body fluid samples. The measured concentration of each of soluble oxidized low-density lipoprotein receptor 1 and neutrophil elastase are combined using a function that converts the assay results into a single composite result to thereby provide a combined concentration of soluble oxidized low-density lipoprotein receptor 1 and neutrophil elastase for the subject. The combined concentration of soluble oxidized low-density lipoprotein receptor 1 and neutrophil elastase is compared to a threshold combined concentration; and the assay results are correlated to the renal status of the subject. The correlating comprises (i) assigning a diagnosis that reduced or worsening renal function or an event an event associated with reduced or worsening renal function has occurred, or assigning a risk or likelihood that reduced or worsening renal function or an event an event associated with reduced or worsening renal function is likely to occur in future, when the combined concentration of soluble oxidized low-density lipoprotein receptor 1 and neutrophil elastase is above the threshold concentration; or (ii) assigning a diagnosis that reduced or worsening renal function or an event an event associated with reduced or worsening renal function has not occurred, or assigning a risk or likelihood that reduced or worsening renal function or an event an event associated with reduced or worsening renal function is not likely to occur in future, when the combined concentration of soluble oxidized low-density lipoprotein receptor 1 and neutrophil elastase is below the threshold concentration. Also disclosed is a combined use of antibodies or antibody fragments in a method performed ex vivo on one or more body fluid samples obtained previously from a subject in determining a present or future reduced renal function in the subject, wherein the antibodies or antibody fragments bind independently to (i) neutrophil elastase or an epitope thereof; and (ii) soluble oxidized low-density lipoprotein receptor 1 or an epitope thereof.

140. [704383](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE

NZ - 30.09.2016

Int.Class [G01N 33/48](#) Appl.No 704383 Applicant Astute Medical, Inc. Inventor ANDERBERG, Joseph

Disclosed is a method for evaluating renal status in a subject, comprising: - performing a plurality of assays configured to detect both of the kidney injury markers metalloproteinase inhibitor 2 and beta-2-glycoprotein 1 in one or more body fluid samples obtained previously from the subject by contacting the body fluid sample(s) with molecules that bind to each of metalloproteinase inhibitor 2 and beta-2-glycoprotein 1 under conditions sufficient for such binding to occur; - determining a measured concentration of each of metalloproteinase inhibitor 2 and beta-2-glycoprotein 1 from the amounts of the molecules bound thereto in the body fluid sample(s); - combining the measured concentration of each of metalloproteinase inhibitor 2 and beta-2-glycoprotein 1 using a function that converts the assay results into a single composite result to thereby provide a combined concentration of metalloproteinase inhibitor 2 and beta-2-glycoprotein 1 for the subject; - comparing the combined concentration of metalloproteinase inhibitor 2 and beta-2-glycoprotein 1 to a threshold combined concentration; and - correlating the assay results to the renal status of the subject.

141. [2014271124](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE

AU - 18.12.2014

Int.Class [G01N 33/48](#) Appl.No 2014271124 Applicant Astute Medical, Inc. Inventor Anderberg, Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a plurality of assays, one or more of which is configured to detect a kidney injury marker selected from the group consisting of metalloproteinase inhibitor 2, soluble oxidized low-density lipoprotein receptor 1, interleukin-2, von Willebrand factor, granulocyte-macrophage colony-stimulating factor, tumor necrosis factor receptor superfamily member 11 B, neutrophil elastase, interleukin-1 beta, heart-type fatty acid-binding protein, beta-2-glycoprotein 1, soluble CD40 ligand, coagulation factor VII, C-C motif chemokine 2, IgM, CA 19-9, IL-10, TNF- $\alpha$ , and myoglobin as diagnostic and prognostic biomarkers in renal injuries.

142. [2774223](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE

CA - 24.03.2011



Int.Class [G01N 33/48](#) Appl.No 2774223 Applicant ASTUTE MEDICAL, INC. Inventor ANDERBERG, JOSEPH

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a plurality of assays, one or more of which is configured to detect a kidney injury marker selected from the group consisting of metalloproteinase inhibitor 2, soluble oxidized low- density lipoprotein receptor 1, interleukin-2, von Willebrand factor, granulocyte- macrophage colony- stimulating factor, tumor necrosis factor receptor superfamily member HB, neutrophil elastase, interleukin- 1 beta, heart- type fatty acid-binding protein, beta-2-glycoprotein 1, soluble CD40 ligand, coagulation factor VII, C-C motif chemokine 2, IgM, CA 19-9, IL-10, TNF- $\alpha$ , and myoglobin as diagnostic and prognostic biomarkers in renal injuries.

143. [2010295287](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE AU - 26.04.2012

Int.Class [G01N 33/48](#) Appl.No 2010295287 Applicant Astute Medical, Inc. Inventor Anderberg, Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a plurality of assays, one or more of which is configured to detect a kidney injury marker selected from the group consisting of metalloproteinase inhibitor 2, soluble oxidized low- density lipoprotein receptor 1, interleukin-2, von Willebrand factor, granulocyte- macrophage colony- stimulating factor, tumor necrosis factor receptor superfamily member HB, neutrophil elastase, interleukin- 1 beta, heart- type fatty acid-binding protein, beta-2-glycoprotein 1, soluble CD40 ligand, coagulation factor VII, C-C motif chemokine 2, IgM, CA 19-9, IL-10, TNF- $\alpha$ , and myoglobin as diagnostic and prognostic biomarkers in renal injuries.

144. [3218724](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE EP - 20.09.2017

Int.Class [G01N 33/68](#) Appl.No 15859966 Applicant ASTUTE MEDICAL INC Inventor ANDERBERG JOSEPH

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect Interleukin-18 -binding protein as diagnostic and prognostic biomarker assays in renal injuries.

145. [3568695](#) METHODS AND COMPOSITIONS FOR EVALUATION AND TREATMENT OF RENAL INJURY AND RENAL FAILURE BASED ON C-C MOTIF CHEMOKINE LIGAND 14 MEASUREMENT EP - 20.11.2019

Int.Class [G01N 33/48](#) Appl.No 18738815 Applicant ASTUTE MEDICAL INC Inventor KAMPF JAMES PATRICK

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect C-C motif chemokine 14 as diagnostic and prognostic biomarker assays in renal injuries.

146. [2018207151](#) METHODS AND COMPOSITIONS FOR EVALUATION AND TREATMENT OF RENAL INJURY AND RENAL FAILURE BASED ON C-C MOTIF CHEMOKINE LIGAND 14 MEASUREMENT AU - 19.07.2018

Int.Class [G01N 33/48](#) Appl.No 2018207151 Applicant Astute Medical, Inc. Inventor Chalfin, Donald

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect C-C motif chemokine 14 as diagnostic and prognostic biomarker assays in renal injuries.

147. [3049444](#) METHODS AND COMPOSITIONS FOR EVALUATION AND TREATMENT OF RENAL INJURY AND RENAL FAILURE BASED ON C-C MOTIF CHEMOKINE LIGAND 14 MEASUREMENT CA - 19.07.2018

Int.Class [G01N 33/48](#) Appl.No 3049444 Applicant ASTUTE MEDICAL, INC. Inventor

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect C-C motif chemokine 14 as diagnostic and prognostic biomarker assays in renal injuries.

148. [2962109](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE EP - 06.01.2016

Int.Class [G01N 33/68](#) Appl.No 14756519 Applicant ASTUTE MEDICAL INC Inventor ANDERBERG JOSEPH

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Coagulation factor X, Coagulation factor V, soluble Receptor tyrosine- protein kinase erbB-2, Interferon beta, C- type lectin domain family 11 member A, Glyceraldehyde- 3 -phosphate dehydrogenase, Interferon omega- 1, Coagulation factor VIII, Thrombin- Antithrombin- III complex, and soluble Tumor necrosis factor ligand superfamily member 13B as diagnostic and prognostic biomarkers in renal injuries.

149. [20160003850](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE US - 07.01.2016

Int.Class [G01N 33/68](#) Appl.No 14770442 Applicant ASTUTE MEDICAL, INC. Inventor Joseph ANDERBERG

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Coagulation factor X, Coagulation factor V, soluble Receptor tyrosine-protein kinase erbB-2, Interferon beta, C- type lectin domain family 11 member A, Glyceraldehyde-3-phosphate dehydrogenase, Interferon omega-1, Coagulation factor VIII, Thrombin-Antithrombin-III complex, and soluble Tumor necrosis factor ligand superfamily member 13B as diagnostic and prognostic biomarkers in renal injuries.



150. [WO/2014/134223](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE WO - 04.09.2014

Int.Class [G01N 33/566](#) Appl.No PCT/US2014/018804 Applicant ASTUTE MEDICAL, INC. Inventor ANDERBERG, Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Coagulation factor X, Coagulation factor V, soluble Receptor tyrosine- protein kinase erbB-2, Interferon beta, C-type lectin domain family 11 member A, Glyceraldehyde- 3 -phosphate dehydrogenase, Interferon omega- 1, Coagulation factor VIII, Thrombin-Antithrombin- III complex, and soluble Tumor necrosis factor ligand superfamily member 13B as diagnostic and prognostic biomarkers in renal injuries.

151. [202037031410](#) ANTIBODIES AND ASSAYS FOR CCL14 IN - 21.08.2020

Int.Class [C07K 16/24](#) Appl.No 202037031410 Applicant ASTUTE MEDICAL, INC. Inventor VIJAYENDRAN, Ravi A.

The invention provides CCL14 antibodies.

152. [20160123996](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE US - 05.05.2016

Int.Class [G01N 33/68](#) Appl.No 14987569 Applicant ASTUTE MEDICAL, INC. Inventor Joseph ANDERBERG

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Prostatic acid phosphatase, Lactotransferrin, Soluble erythropoietin receptor, Von Willebrand factor, Soluble endothelial protein C receptor, and Beta-2-glycoprotein 1 as diagnostic and prognostic biomarkers in renal injuries.

153. [20210061900](#) ANTIBODIES AND ASSAYS FOR CCL14 US - 04.03.2021

Int.Class [C07K 16/24](#) Appl.No 16958072 Applicant ASTUTE MEDICAL, INC. Inventor RAVI A. VIJAYENDRAN

The invention provides CCL14 antibodies.

154. [2361018](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE EP - 31.08.2011

Int.Class [G01N 33/68](#) Appl.No 09825600 Applicant ASTUTE MEDICAL INC Inventor ANDERBERG JOSEPH

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Clusterin, Heart- type fatty acid binding protein, Hepatocyte growth factor, Interferon gamma, Interleukin- 12 subunit beta, Interleukin-16, Interleukin-2, 72 kDa type IV collagenase, Matrix metalloproteinase-9, Midkine, and Serum amyloid P-component as diagnostic and prognostic biomarkers in renal injuries.

155. [2751424](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE CA - 12.08.2010

Int.Class [G01N 33/48](#) Appl.No 2751424 Applicant ASTUTE MEDICAL, INC. Inventor ANDERBERG, JOSEPH

Disclosed are methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, disclosed are assays that detect one or more markers selected from the group consisting of Prostatic acid phosphatase, Lactotransferrin, Soluble erythropoietin receptor, Von Willebrand factor, Soluble endothelial protein C receptor, and Beta-2- glycoprotein 1 as diagnostic and prognostic biomarkers in renal injuries.

156. [2742113](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE CA - 14.05.2010

Int.Class [G01N 33/48](#) Appl.No 2742113 Applicant ASTUTE MEDICAL, INC. Inventor ANDERBERG, JOSEPH

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Clusterin, Heart- type fatty acid binding protein, Hepatocyte growth factor, Interferon gamma, Interleukin- 12 subunit beta, Interleukin-16, Interleukin-2, 72 kDa type IV collagenase, Matrix metalloproteinase-9, Midkine, and Serum amyloid P-component as diagnostic and prognostic biomarkers in renal injuries.

157. [2913676](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE EP - 02.09.2015

Int.Class [G01N 33/68](#) Appl.No 15161638 Applicant ASTUTE MEDICAL INC Inventor ANDERBERG JOSEPH

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect Hepatocyte growth factor and optionally one or more markers selected from the group consisting of Clusterin, Heart- type fatty acid binding protein, Interferon gamma, Interleukin- 12 subunit beta, Interleukin-16, Interleukin-2, 72 kDa type IV collagenase, Matrix metalloproteinase-9, Midkine, and Serum amyloid P-component as diagnostic and prognostic biomarkers in renal injuries.

158. [2011004767](#) METODOS Y COMPOSICIONES PARA DIAGNOSIS Y PROGNOSIS DE LESION RENAL Y FALLA RENAL. MX - 06.09.2011

Int.Class [A01N 59/00](#) Appl.No 2011004767 Applicant ASTUTE MEDICAL, INC.\* Inventor ANDERBERG, Joseph



The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Clusterin, Heart-type fatty acid binding protein, Hepatocyte growth factor, Interferon gamma, Interleukin-12 subunit beta, Interleukin-16, Interleukin-2, 72 kDa type IV collagenase, Matrix metalloproteinase-9, Midkine, and Serum amyloid P-component as diagnostic and prognostic biomarkers in renal injuries.

159. [2011008323](#) METODOS Y COMPOSICIONES PARA DIAGNOSIS Y PROGNOSIS DE LESION RENAL Y FALLA RENAL. MX - 21.09.2011

Int.Class [C12Q 1/42](#) Appl.No 2011008323 Applicant ASTUTE MEDICAL, INC. Inventor ANDERBERG, Joseph

Disclosed are methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, disclosed are assays that detect one or more markers selected from the group consisting of Prostatic acid phosphatase, Lactotransferin, Soluble erythropoietin receptor, Von Willebrand factor, Soluble endothelial protein C receptor, and Beta-2-glycoprotein 1 as diagnostic and prognostic biomarkers in renal injuries.

160. [2393937](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE EP - 14.12.2011

Int.Class [C12Q 1/42](#) Appl.No 10739150 Applicant ASTUTE MEDICAL INC Inventor ANDERBERG JOSEPH

Disclosed are methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, disclosed are assays that detect one or more markers selected from the group consisting of Prostatic acid phosphatase, Lactotransferin, Soluble erythropoietin receptor, Von Willebrand factor, Soluble endothelial protein C receptor, and Beta-2-glycoprotein 1 as diagnostic and prognostic biomarkers in renal injuries.

161. [609666](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE NZ - 28.11.2014

Int.Class [C12Q 1/42](#) Appl.No 609666 Applicant Astute Medical, Inc. Inventor ANDERBERG, Joseph

Disclosed is an ex vivo method for evaluating renal status in a subject, comprising: performing one or more assays configured to detect Soluble endothelial protein C receptor in a body fluid sample obtained previously from the subject to provide one or more assay results, wherein an assay configured to detect Soluble endothelial protein C receptor comprises contacting the body fluid sample with one or more antibodies or antibody fragments that bind to Soluble endothelial protein C receptor or part thereof, to thereby form a complex, and determining a measured concentration of Soluble endothelial protein C receptor in the body fluid sample based on an amount of the complex formed; and correlating the assay result(s) to one or more of risk stratification, staging, prognosis, classifying and monitoring of the renal status of the subject, wherein said correlating comprises comparing the measured concentration of Soluble endothelial protein C receptor to a threshold concentration of Soluble endothelial protein C receptor, and assigning a likelihood of a future event occurring or determining that an event has occurred when the measured concentration varies from the threshold, or assigning a likelihood of a future event not occurring or determining that an event has not occurred when the measured concentration does not vary from the threshold.

162. [630621](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE NZ - 31.03.2016

Int.Class [C12Q 1/42](#) Appl.No 630621 Applicant Astute Medical, Inc. Inventor ANDERBERG, Joseph

Disclosed is an ex vivo method for evaluating renal status in a subject, comprising: - performing one or more assays configured to detect one or more kidney injury markers present in a body fluid sample obtained previously from the subject, wherein at least one kidney injury marker is Lactotransferrin; - determining on the body fluid sample one or more assay result(s); and - correlating the assay result(s) to one or more of risk stratification, staging, prognosis, classifying and monitoring of the renal status of the subject, wherein said correlating comprises comparing a measured concentration of Lactoferrin to a threshold concentration of Lactoferrin and assigning a likelihood of a future event occurring or determining that an event has occurred when the measured concentration varies from the threshold, or assigning a likelihood of a future event not occurring or determining that an event has not occurred when the measured concentration does not vary from a threshold.

163. [592488](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE NZ - 26.10.2012

Int.Class [A01N 59/00](#) Appl.No 592488 Applicant Astute Medical, Inc. Inventor ANDERBERG, Joseph

Patent 592488 Disclosed are methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Clusterin, Heart-type fatty acid binding protein, Hepatocyte growth factor, Interferon gamma, Interleukin-12 subunit beta, Interleukin-16, Interleukin-2, 72 kDa type IV collagenase, Matrix metalloproteinase-9, Midkine, and Serum amyloid P-component as diagnostic and prognostic biomarkers in renal injuries.

164. [PI0922021](#) MÉTODO PARA AVALIAR A CONDIÇÃO RENAL EM UM INDIVÍDUO, E, USO DE UM OU MAIS MARCADORES DE LESÃO RENAL BR - 24.09.2019

Int.Class [A01N 59](#) Appl.No PI0922021 Applicant Astute Medical, INC. Inventor Jeff Gray

abstract not available

165. [PI1007917](#) MÉTODO PARA AVALIAR A SITUAÇÃO RENAL EM UM INDIVÍDUO, E, USO DE UM OU MAIS MARCADORES DE LESÃO RENAL BR - 24.09.2019

Int.Class [C12Q 1](#) Appl.No PI1007917 Applicant Astute Medical, Inc Inventor Jeff Gray

abstract not available



166. [1133/MUMNP/2011](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND INJURY AND RENAL FAILURE IN - 30.12.2011

Int.Class [A01N 59/00](#) Appl.No 1133/MUMNP/2011 Applicant Astute Medical Inc. Inventor ANDERBERG Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Clusterin, Heart-type fatty acid binding protein, Hepatocyte growth factor, Interferon gamma, Interleukin-12 subunit beta, Interleukin-16, Interleukin-2, 72 kDa type IV collagenase, Matrix metalloproteinase-9, Midkine, and Serum amyloid P-component as diagnostic and prognostic biomarkers in renal injuries.

167. [1628/MUMNP/2011](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE IN - 20.01.2012

Int.Class [C12Q 1/42](#) Appl.No 1628/MUMNP/2011 Applicant ASTUTE MEDICAL INC. Inventor ANDERBERG Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Prostatic acid phosphatase, Lactotransferrin, Soluble erythropoietin receptor, Von Willebrand factor, Soluble endothelial protein C receptor, and Beta-2-glycoprotein 1 as diagnostic and prognostic biomarkers in renal injuries.

168. [20170030927](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE US - 02.02.2017

Int.Class [G01N 33/68](#) Appl.No 15295746 Applicant ASTUTE MEDICAL, INC. Inventor Joseph Anderberg

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Clusterin, Heart-type fatty acid binding protein, Hepatocyte growth factor, Interferon gamma, Interleukin-12 subunit beta, Interleukin-16, Interleukin-2, 72 kDa type IV collagenase, Matrix metalloproteinase-9, Midkine, and Serum amyloid P-component as diagnostic and prognostic biomarkers in renal injuries.

169. [2015200266](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE AU - 12.02.2015

Int.Class [A01N 59/00](#) Appl.No 2015200266 Applicant Astute Medical, Inc. Inventor Anderberg, Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Clusterin, Heart type fatty acid binding protein, Hepatocyte growth factor, Interferon gamma, Interleukin-12 subunit beta, Interleukin-16, Interleukin-2, 72 kDa type IV collagenase, Matrix metalloproteinase-9, Midkine, and Serum amyloid P-component as diagnostic and prognostic biomarkers in renal injuries.

170. [20160054336](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE US - 25.02.2016

Int.Class [G01N 31/00](#) Appl.No 14673353 Applicant ASTUTE MEDICAL, INC. Inventor Joseph Anderberg

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Clusterin, Heart-type fatty acid binding protein, Hepatocyte growth factor, Interferon gamma, Interleukin-12 subunit beta, Interleukin-16, Interleukin-2, 72 kDa type IV collagenase, Matrix metalloproteinase-9, Midkine, and Serum amyloid P-component as diagnostic and prognostic biomarkers in renal injuries.

171. [594770](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE NZ - 23.04.2013

Int.Class [C12Q 1/42](#) Appl.No 594770 Applicant Astute Medical, Inc. Inventor ANDERBERG, Joseph

172. [106546752](#) DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE CN - 29.03.2017

Int.Class [G01N 33/68](#) Appl.No 201611051979.0 Applicant ASTUTE MEDICAL, INC. Inventor ANDERBERG JOSEPH

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Prostatic acid phosphatase, Lactotransferrin, Soluble erythropoietin receptor, Von Willebrand factor, Soluble endothelial protein C receptor, and Beta-2-glycoprotein 1 as diagnostic and prognostic biomarkers in renal injuries.

173. [2009313189](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE AU - 26.05.2011

Int.Class [A01N 59/00](#) Appl.No 2009313189 Applicant Astute Medical, Inc. Inventor Anderberg, Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Clusterin, Heart-type fatty acid binding protein, Hepatocyte growth factor, Interferon gamma, Interleukin-12 subunit beta, Interleukin-16, Interleukin-2, 72 kDa type IV collagenase, Matrix metalloproteinase-9, Midkine, and Serum amyloid P-component as diagnostic and prognostic biomarkers in renal injuries.



174. [2010210535](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE AU - 15.09.2011

Int.Class [C12Q 1/42](#) Appl.No 2010210535 Applicant Astute Medical, Inc. Inventor Anderberg, Joseph

Disclosed are methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, disclosed are assays that detect one or more markers selected from the group consisting of Prostatic acid phosphatase, Lactotransferin, Soluble erythropoietin receptor, Von Willebrand factor, Soluble endothelial protein C receptor, and Beta-2-glycoprotein 1 as diagnostic and prognostic biomarkers in renal injuries.

175. [WO/2019/133902](#) ANTIBODIES AND ASSAYS FOR CCL14 WO - 04.07.2019

Int.Class [C07K 16/24](#) Appl.No PCT/US2018/068000 Applicant ASTUTE MEDICAL, INC. Inventor VIJAYENDRAN, Ravi A.

The invention provides CCL14 antibodies.

176. [3732196](#) ANTIBODIES AND ASSAYS FOR CCL14 EP - 04.11.2020

Int.Class [C07K 16/24](#) Appl.No 18893753 Applicant ASTUTE MEDICAL INC Inventor VIJAYENDRAN RAVI A

The invention provides CCL14 antibodies.

177. [WO/2022/109140](#) METHODS AND COMPOSITIONS FOR TREATMENT OF RENAL INJURY AND RENAL FAILURE WO - 27.05.2022

Int.Class [A61K 35/14](#) Appl.No PCT/US2021/059897 Applicant ASTUTE MEDICAL, INC. Inventor MCPHERSON, Paul

A method of devising a therapy plan for renal replacement therapy (RRT) includes detecting a level of one or more biomarkers in a body fluid sample obtained from a subject. The level(s) may be correlated to an expected benefit from treatment with continued RRT and/or to an expected ability to successfully discontinue RRT. The method may include the step of assigning the subject to a predetermined subpopulation of individuals exhibiting a known status with regard to meeting criteria for continuing or discontinuing RRT. In some embodiments, the biomarker level is detected by introducing the body fluid into an assay instrument and contacting the body fluid to a binding reagent, for example, an antibody.

178. [624614](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE NZ - 30.10.2015

Int.Class [A61K 39/395](#) Appl.No 624614 Applicant Astute Medical, Inc. Inventor ANDERBERG, Joseph

Disclosed is a method for evaluating renal status in a subject ex vivo, comprising: performing one or more assays configured to detect C-C motif chemokine 23 on a body fluid sample obtained previously from the subject; determining one or more assay result(s) each assay result comprising a measured concentration of C-C motif chemokine 23; and correlating the assay result(s) to the renal status of the subject, the correlating comprising comparing a measured concentration of C-C motif chemokine 23 to a threshold concentration of C-C motif chemokine 23 and assigning a likelihood or non-likelihood of an event occurring or having occurred when the measured concentration varies from the threshold. Also disclosed is the use of a kit comprising reagents for detecting detect C-C motif chemokine 23 to evaluate renal status in a subject ex vivo.

179. [600160](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE NZ - 30.05.2014

Int.Class [A61K 39/395](#) Appl.No 600160 Applicant Astute Medical, Inc. Inventor ANDERBERG, Joseph

Disclosed is a method for evaluating renal status in a subject, comprising: performing one or more assays ex vivo, each assay being configured to detect one or more kidney injury markers present in a body fluid sample obtained previously from the subject, wherein at least one of said kidney injury markers is soluble transmembrane glycoprotein NMB; determining one or more assay result(s) each assay result comprising a measured level of the one or more kidney injury markers including soluble transmembrane glycoprotein NMB; and correlating the assay result(s) to the renal status of the subject, said correlating comprising comparing a measured concentration of the one or more kidney injury markers including soluble transmembrane glycoprotein NMB to a threshold concentration of the one or more kidney injury markers including soluble transmembrane glycoprotein NMB and assigning a likelihood or non-likelihood of an event occurring or having occurred when the measured concentration varies from the threshold.

180. [1109/MUMNP/2012](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE IN - 04.10.2013

Int.Class [A61K 39/395](#) Appl.No 1109/MUMNP/2012 Applicant ASTUTE MEDICAL INC. Inventor ANDERBERG Joseph

The present invention relates to methods and compositions for monitoring diagnosis prognosis and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of C-C motif chemokine 23 Transmembrane glycoprotein NMB Brain-derived neurotrophic factor Cathepsin S Transforming growth factor beta-2 Urokinase-type plasminogen activator Angiotensin-2 Matrilysin Carcinoembryonic antigen-related cell adhesion molecule 1 Creatine kinase MB Insulin Immunoglobulin M Immunoglobulin E Macrophage migration inhibitory factor Galectin-3 Transforming growth factor beta-3 Heparan sulfate soluble Cadherin-3 Complement C5 Platelet factor 4 Platelet basic protein and Stromelysin-2 as diagnostic and prognostic biomarkers in renal injuries.

181. [2010314999](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE AU - 14.06.2012

Int.Class [A61K 39/395](#) Appl.No 2010314999 Applicant Astute Medical, Inc. Inventor Anderberg, Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of C-C motif chemokine 23, Transmembrane glycoprotein NMB, Brain- derived neurotrophic factor, Cathepsin S, Transforming growth factor beta-2, Urokinase- type plasminogen activator, Angiotensin-2, Matrilysin, Carcinoembryonic antigen- related cell adhesion molecule 1, Creatine kinase MB, Insulin, Immunoglobulin M, Immunoglobulin E, Macrophage migration inhibitory factor, Galectin-3, Transforming growth factor beta-3, Heparan sulfate, soluble Cadherin-3, Complement C5, Platelet factor 4, Platelet basic protein, and Stromelysin-2 as diagnostic and prognostic biomarkers in renal injuries.

182. [3153863](#) METHODS AND USES FOR EVALUATION OF ACUTE RENAL FAILURE/ACUTE RENAL INJURY EP - 12.04.2017

Int.Class [G01N 33/68](#) Appl.No 16196505 Applicant ASTUTE MEDICAL INC Inventor ANDERBERG JOSEPH

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect soluble Transmembrane glycoprotein NMB, and optionally further a kidney injury marker of C-C motif chemokine 23, Brain-derived neurotrophic factor, Cathepsin S, Transforming growth factor beta-2, Urokinase-type plasminogen activator, Angiotensin-converting enzyme 2, Matrilysin, Carcinoembryonic antigen-related cell adhesion molecule 1, Creatine kinase MB, Insulin, Immunoglobulin M, Immunoglobulin E, Macrophage migration inhibitory factor, Galectin-3, Transforming growth factor beta-3, Heparan sulfate, soluble Cadherin-3, Complement C5, Platelet factor 4, Platelet basic protein, and Stromelysin-2 as diagnostic and prognostic biomarkers in renal injuries.

183. [629512](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE NZ - 22.02.2017

Int.Class [C12Q 1/00](#) Appl.No 629512 Applicant ASTUTE MEDICAL, INC. Inventor ANDERBERG, Joseph

184. [20150293085](#) QUANTITATIVE LATERAL FLOW ASSAY US - 15.10.2015

Int.Class [G01N 33/543](#) Appl.No 14439528 Applicant ASTUTE MEDICAL, INC. Inventor Joseph Anderberg

The present invention relates to devices, kits, instruments and methods for quantitatively detecting multiple analytes in a sample. More specifically, the present invention relates to devices, kits, instruments and methods for quantitatively detecting multiple analytes with desired or targeted precision, and the uses thereof.

185. [2015230791](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE AU - 15.10.2015

Int.Class [G01N 33/48](#) Appl.No 2015230791 Applicant Astute Medical, Inc. Inventor

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Cytoplasmic aspartate aminotransferase, soluble Tumor necrosis factor receptor superfamily member 5, soluble CD40 Ligand, soluble C-X-C Motif chemokine 16, S100-A12, Eotaxin, soluble E-selectin, Fibronectin, Granulocyte colony-stimulating factor, Granulocyte macrophage colony-stimulating factor, Heparin-binding growth factor 2, soluble Hepatocyte growth factor receptor, Interleukin-1 receptor antagonist, Interleukin-1 beta, Interleukin-10, Interleukin-15, Interleukin-3, Myeloperoxidase, Nidogen-1, soluble Oxidized low-density lipoprotein receptor 1, Pappalysin-1, soluble P-selectin glycoprotein ligand 1, Antileukoproteinase, soluble Kit ligand, Tissue inhibitor of metalloproteinase 1, Tissue inhibitor of metalloproteinase 2, soluble Tumor necrosis factor, soluble Vascular cell adhesion molecule 1, and Vascular endothelial growth factor A as diagnostic and prognostic biomarkers in renal injuries.

186. [2923204](#) QUANTITATIVE LATERAL FLOW ASSAY EP - 30.09.2015

Int.Class [G01N 33/558](#) Appl.No 13789666 Applicant ASTUTE MEDICAL INC Inventor ANDERBERG JOSEPH

The present invention relates to devices, kits, instruments and methods for quantitatively detecting multiple analytes in a sample. More specifically, the present invention relates to devices, kits, instruments and methods for quantitatively detecting multiple analytes with desired or targeted precision, and the uses thereof.

187. [1759/MUMNP/2014](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE IN - 03.07.2015

Int.Class [C12Q 1/00](#) Appl.No 1759/MUMNP/2014 Applicant ASTUTE MEDICAL INC. Inventor ANDERBERG Joseph

The present invention relates to methods and compositions for monitoring diagnosis prognosis and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of SPARC Follistatin related protein 1 Tumor necrosis factor receptor superfamily member 21 Growth arrest specific protein 1 MHC class I polypeptide related sequence A Syndecan 1 and WNT1 inducible signaling pathway protein 1 as diagnostic and prognostic biomarkers in renal injuries.

188. [710706](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE NZ - 07.08.2014

Int.Class [G01N 33/53](#) Appl.No 710706 Applicant ASTUTE MEDICAL, INC. Inventor ANDERBERG, Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect Tartrate-resistant acid phosphatase type 5 as diagnostic and prognostic biomarker assays in renal injuries.

189. [104379758](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE CN - 25.02.2015

Int.Class [C12Q 1/00](#) Appl.No 201380020012.4 Applicant ASTUTE MEDICAL, INC. Inventor ANDERBERG JOSEPH

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of SPARC, Follistatin-related protein 1, Tumor necrosis factor receptor superfamily member 21, Growth arrest-specific protein 1, MHC class I polypeptide-related sequence A, Syndecan-1, and WNT1-inducible-signaling pathway protein 1 as diagnostic and prognostic biomarkers in renal injuries.

190. [2013226181](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE AU - 18.09.2014

Int.Class [C12Q 1/00](#) Appl.No 2013226181 Applicant Astute Medical, Inc. Inventor Anderberg, Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of SPARC, Follistatin-related protein 1, Tumor necrosis factor receptor superfamily member 21, Growth arrest-specific protein 1, MHC class I polypeptide-related sequence A, Syndecan-1, and WNT1-inducible-signaling pathway protein 1 as diagnostic and prognostic biomarkers in renal injuries.

191. [2014212609](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE AU - 20.08.2015

Int.Class [G01N 33/53](#) Appl.No 2014212609 Applicant Astute Medical, Inc. Inventor Anderberg, Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect Tartrate-resistant acid phosphatase type 5 as diagnostic and prognostic biomarker assays in renal injuries.

192. [2865559](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE CA - 06.09.2013

Int.Class [G01N 33/48](#) Appl.No 2865559 Applicant ASTUTE MEDICAL, INC. Inventor

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of SPARC, Follistatin-related protein 1, Tumor necrosis factor receptor superfamily member 21, Growth arrest-specific protein 1, MHC class I polypeptide-related sequence A, Syndecan-1, and WNT1-inducible-signaling pathway protein 1 as diagnostic and prognostic biomarkers in renal injuries.

193. [20150010929](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE US - 08.01.2015

Int.Class [G01N 33/68](#) Appl.No 14381532 Applicant ASTUTE MEDICAL, INC. Inventor Anderberg Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of SPARC, Follistatin-related protein 1, Tumor necrosis factor receptor superfamily member 21, Growth arrest-specific protein 1, MHC class I polypeptide-related sequence A, Syndecan-1, and WNT1-inducible-signaling pathway protein 1 as diagnostic and prognostic biomarkers in renal injuries.

194. [20160011194](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE US - 14.01.2016

Int.Class [G01N 33/573](#) Appl.No 14764139 Applicant ASTUTE MEDICAL, INC. Inventor Joseph Anderberg

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect Tartrate-resistant acid phosphatase type 5 as diagnostic and prognostic biomarker assays in renal injuries.

195. [723256](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE NZ - 22.03.2018

Int.Class [C12Q 1/00](#) Appl.No 723256 Applicant ASTUTE MEDICAL, INC. Inventor ANDERBERG, Joseph

196. [WO/2014/120677](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE WO - 07.08.2014

Int.Class [G01N 33/53](#) Appl.No PCT/US2014/013433 Applicant ASTUTE MEDICAL, INC. Inventor ANDERBERG, Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect Tartrate-resistant acid phosphatase type 5 as diagnostic and prognostic biomarker assays in renal injuries.

197. [WO/2014/070935](#) QUANTITATIVE LATERAL FLOW ASSAY WO - 08.05.2014

Int.Class [G01N 33/558](#) Appl.No PCT/US2013/067585 Applicant ASTUTE MEDICAL, INC. Inventor ANDERBERG, Joseph

The present invention relates to devices, kits, instruments and methods for quantitatively detecting multiple analytes in a sample. More specifically, the present invention relates to devices, kits, instruments and methods for quantitatively detecting multiple analytes with desired or targeted precision, and the uses thereof.

198. [2014224137](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE AU - 02.10.2014



Int.Class [A61K 39/395](#) Appl.No 2014224137 Applicant Astute Medical, Inc. Inventor Anderberg, Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of C-C motif chemokine 23, Transmembrane glycoprotein NMB, Brain derived neurotrophic factor, Cathepsin S, Transforming growth factor beta-2, Urokinase type plasminogen activator, Angiopoietin-2, Matrilysin, Carcinoembryonic antigen related cell adhesion molecule 1, Creatine kinase MB, Insulin, Immunoglobulin M, Immunoglobulin E, Macrophage migration inhibitory factor, Galectin-3, Transforming growth factor beta-3, Heparan sulfate, soluble Cadherin-3, Complement C5, Platelet factor 4, Platelet basic protein, and Stromelysin-2 as diagnostic and prognostic biomarkers in renal injuries.

199. [102711827](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE CN - 03.10.2012

Int.Class [A61K 39/395](#) Appl.No 201080057014.7 Applicant Astute Medical Inc. Inventor Anderberg Joseph

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of C-C motif chemokine 23, Transmembrane glycoprotein NMB, Brain-derived neurotrophic factor, Cathepsin S, Transforming growth factor beta-2, Urokinase-type plasminogen activator, Angiopoietin-2, Matrilysin, Carcinoembryonic antigen-related cell adhesion molecule 1, Creatine kinase MB, Insulin, Immunoglobulin M, Immunoglobulin E, Macrophage migration inhibitory factor, Galectin-3, Transforming growth factor beta-3, Heparan sulfate, soluble Cadherin-3, Complement C5, Platelet factor 4, Platelet basic protein, and Stromelysin-2 as diagnostic and prognostic biomarkers in renal injuries.

200. [2779905](#) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE CA - 12.05.2011

Int.Class [G01N 33/48](#) Appl.No 2779905 Applicant ASTUTE MEDICAL, INC. Inventor ANDERBERG, JOSEPH

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of C-C motif chemokine 23, Transmembrane glycoprotein NMB, Brain-derived neurotrophic factor, Cathepsin S, Transforming growth factor beta-2, Urokinase-type plasminogen activator, Angiopoietin-2, Matrilysin, Carcinoembryonic antigen-related cell adhesion molecule 1, Creatine kinase MB, Insulin, Immunoglobulin M, Immunoglobulin E, Macrophage migration inhibitory factor, Galectin-3, Transforming growth factor beta-3, Heparan sulfate, soluble Cadherin-3, Complement C5, Platelet factor 4, Platelet basic protein, and Stromelysin-2 as diagnostic and prognostic biomarkers in renal injuries.

